| 1.
|  | Dankner WM, Lindsey JC, Levin MJ, et al. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001;20:40-8. |
|
| 2.
| | Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-8. |
|
| 3.
| | Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006;296:292-300. |
|
| 4.
| | Nesheim SR, Kapogiannis BG, Soe MM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics 2007;120:00 100–9. |
|
| 5.
| | Ylitalo N, Brogly S, Hughes MD, et al. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Pediatr Adolesc Med 2006;160:778-87. |
|
| 6.
| | CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995;44(No. RR-8). |
|
| 7.
| | CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. |
|
| 8.
| | CDC. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR 1999;48(No. RR-10). |
|
| 9.
| | Mofenson LM, Oleske J, Serchuck L, et al. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. The most recent information is available at http://aidsinfo.nih.gov. Clin Infect Dis 2005;40(Supp 1):S184. |
|
| 10.
| | Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001;34:223-9. |
|
| 11.
| | Kovacs A, Schluchter M, Easley K, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 1999;341:77-84. |
|
| 12.
| | Gutman LT, Moye J, Zimmer B, et al. Tuberculosis in human immunodeficiency virus-exposed or -infected United States children. Pediatr Infect Dis J 1994;13:963-8. |
|
| 13.
| | Lindegren ML, Steinberg S, Byers R. Epidemiology of HIV/AIDS in children. Pediatr Clin North Am 2000;47:1-20. |
|
| 14.
| | Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. February 23, 2009. Available at http:// aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. The most recent information is vailable at: http://aidsinfo.nih.gov. |
|
| 15.
| | CDC. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR 2002;51(No. RR-8). |
|
| 16.
| | CDC. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. |
|
| 17.
| | Kish MA, Infectious Diseases Society of America. Guide to development of practice guidelines. Clin Infect Dis 2001;32:851-4. |
|
| 18.
| | Bohjanen PR, Boulware DR. Immune reconstitution inflammatory syndrome. In: Volberding P, Sande MA, Lange J, Greene W. eds. Global HIV/AIDS Medicine. Philadelphia, PA: Elsevier; 2007:193-205. 100 MMWR September 4, 2009 |
|
| 19.
| | Murdoch DM, Venter WD, Van Rie A, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007;4 (May 8):9. |
|
| 20.
| | Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, et al. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J Allergy Clin Immunol 2004;113:742-6. |
|
| 21.
| | Nuttall JJ, Wilmshurst JM, Ndondo AP, et al. Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis J 2004;23:683-5. |
|
| 22.
| | Puthanakit T, Oberdorfer P, Punjaisee S, et al. Immune reconstitution syndrome due to bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005;41:1049-52. |
|
| 23.
| | Puthanakit T, Oberdorfer P, Ukarapol N, et al. Immune reconstitution syndrome from nontuberculous mycobacterial infection after initiation of antiretroviral therapy in children with HIV infection. Pediatr Infect Dis J 2006;25:645-8. |
|
| 24.
| | Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J 2006;25:53-8. |
|
| 25.
| | Siberry GK, Tessema S. Immune reconstitution syndrome precipitated by bacille Calmette Guerin after initiation of antiretroviral therapy. Pediatr Infect Dis J 2006;25:648-9. |
|
| 26.
| | Kroidl A, Huck K, Weinspach S, et al. Immune reconstitution inflammatory syndrome (IRIS) due to bacille Calmette Guerin (BCG) in an HIV-positive child. Scan J Infect Dis 2006;38:716-8. |
|
| 27.
| | van Toorn R, Rabie H, Warwick JM. Opsoclonus-myoclonus in an HIVinfected child on antiretroviral therapy-possible immune reconstitution inflammatory syndrome. Eur J Paediatr Neurol 2005;9:423-6. |
|
| 28.
| | Alexander A, Rode H. Adverse reactions to the Bacillus Calmette-Guerin vaccine in HIV-positive infants. J Pediatr Surg 2007;42:549-52. |
|
| 29.
| | Robertson J, Meier M, Wall J, et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006;42:1639-46. |
|
| 30.
| | CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-15). |
|
| 31.
| | CDC. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47(No. RR-8). |
|
| 32.
| | CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-4). |
|
| 33.
| | CDC. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2009;58(No. RR-2). |
|
| 34.
| | CDC. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP). MMWR 1991;40(No. RR-1). |
|
| 35.
| | CDC. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR 2008;57(No. RR-7). |
|
| 36.
| | CDC. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(No. RR-9). |
|
| 37.
| | CDC. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(No. RR-5). |
|
| 38.
| | CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: immunization of infants, children, and adolescents. MMWR 2005;54(No. RR-16). |
|
| 39.
| | CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR 2006;55(No. RR-7). |
|
| 40.
| | CDC. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(No. RR-7). |
|
| 41.
| | CDC. Notice to readers: Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR 2007:56:1265-6. |
|
| 42.
| | CDC. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR 1997;46(No. RR-7). |
|
| 43.
| | CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR 2006;55(No. RR-3). |
|
| 44.
| | CDC. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with men ingococcal conjugate vaccine.MMWR 2007;56:794-5. |
|
| 45.
| | Mofenson LM, Korelitz J, Pelton S, et al. Sinusitis in children infected with human immunodeficiency virus: clinical characteristics, risk factors, and prophylaxis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Clin Infect Dis 1995;21:1175-81. |
|
| 46.
| | Nachman S, Gona P, Dankner W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005;115:e488-94. |
|
| 47.
| | Murphy TF HF, Clyde WA, Jr, Collier AM, Denny FW. Pneumonia: an eleven-year study in a pediatric practice. Am J Epidemiol 1981;113: 12-21. |
|
| 48.
| | Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of communityacquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-88. |
|
| 49.
| | Zangwill KM, Vadheim CM, Vannier AM, et al. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis 1996;174:752-9. |
|
| 50.
| | CDC. Active bacterial core surveillance of the Emerging Infections Program Network, Streptococcus pneumoniae, 2003. Available at: www. cdc.gov/ncidod/dbmd/abcs. Accessed February 11, 2005. |
|
| 51.
| | Mofenson LM, Yogev R, Korelitz J, et al. Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Pediatr Infect Dis J 1998;17:872-80. Vol. 58 / RR-11 Recommendations and Reports 101 |
|
| 52.
| | Madhi SA, Petersen K, Madhi A, et al. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis 2000;31:170-6. |
|
| 53.
| | Sharland M, Gibb DM, Holland F. Respiratory morbidity from lymphocytic interstitial pneumonitis (LIP) in vertically acquired HIV infection. Arch Dis Child 1997;76:334-6. |
|
| 54.
| | Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. N Engl J Med 1991;325:73-80. |
|
| 55.
| | Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med 1994;331:1181-7. |
|
| 56.
| | Madhi SA, Petersen K, Madhi A, et al. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000; 19:1141-7. |
|
| 57.
| | Lichenstein R, King JC Jr, Farley JJ, et al. Bacteremia in febrile human immunodeficiency virus-infected children presenting to ambulatory care settings. Pediatr Infect Dis J 1998;17:381-5. |
|
| 58.
| | Farley JJ, King JC Jr, Nair P, et al. Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection. J Pediatr 1994;124:853-8. |
|
| 59.
| | Andiman WA, Simpson J, Holtkamp C, et al. Invasive pneumococcal infections in children infected with HIV are not associated with splenic dysfunction. AIDS Patient Care STDS 1996;10:336-41. |
|
| 60.
| | Mao C, Harper M, McIntosh K, et al. Invasive pneumococcal infections in human immunodeficiency virus-infected children. J Infect Dis 1996;173:870-6. |
|
| 61.
| | Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007;20:11-5. |
|
| 62.
| | Crewe-Brown HH, Karstaedt AS, Saunders GL, et al. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. Clin Infect Dis 1997; 25:1165-72. |
|
| 63.
| | Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349:1341-8. |
|
| 64.
| | Frankel RE, Virata M, Hardalo C, et al. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection. Clin Infect Dis 1996;23:577-84. |
|
| 65.
| | Gímez-Barreto D, Calderín-Jaimes E, Rodríguez RS, et al. Clinical outcome of invasive infections in children caused by highly penicillinresistant Streptococcus pneumoniae compared with infections caused by penicillin-susceptible strains. Arch Med Res 2000;31:592-8. |
|
| 66.
| | Rowland KE, Turnidge JD. The impact of penicillin resistance on the outcome of invasive Streptococcus pneumoniae infection in children. Aust N Z J Med 2000;30:441-9. |
|
| 67.
| | Madhi SA, Petersen K, Khoosal M, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002;21:315-21. |
|
| 68.
| | Nelson CG, Iler MA, Woods CW, et al. Meningococcemia in a patient coinfected with hepatitis C virus and HIV. Emerg Infect Dis 2000;6:646-8. |
|
| 69.
| | Nitta AT, Douglas JM, Arakere G, et al. Disseminated meningococcal infection in HIV-seropositive patients. AIDS 1993;7:87-90. |
|
| 70.
| | Pearson IC, Baker R, Sullivan AK, et al. Meningococcal infection in patients with the human immunodeficiency virus and acquired immunodeficiency syndrome. Int J STD AIDS 2001;12:410-1. |
|
| 71.
| | Kipp W, Kamugisha J, Rehle T. Meningococcal meningitis and HIV infection: results from a case-control study in western Uganda. AIDS 1992;6:1557-8. |
|
| 72.
| | Stephens DS, Hajjeh RA, Baughman WS, et al. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med 1995;123:937-40. |
|
| 73.
| | Rongkavilit C, Rodriguez ZM, Gímez-Marín O, et al. Gram-negative bacillary bacteremia in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2000;19:122-8. |
|
| 74.
| | Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005;352:39-47. |
|
| 75.
| | Roilides E, Marshall D, Venzon D, et al. Bacterial infections in human immunodeficiency virus type 1-infected children: the impact of central venous catheters and antiretroviral agents. Pediatr Infect Dis J 1991;10:813-9. |
|
| 76.
| | Kuhn L, Kasonde P, Sinkala M, et al. Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? Clin Infect Dis 2005;41:1654-61. |
|
| 77.
| | Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr 2006;41:504-8. |
|
| 78.
| | Mussi-Pinhata M, Freimanis L, Yamamoto AY, et al. Infectious disease morbidity among young HIV-1-exposed but uninfected infants in Latin American and Caribbean countries: the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study. Pediatrics 2007;119:e694-704. |
|
| 79.
| | Kattan M, Platzker A, Mellins RB, et al. Respiratory diseases in the first year of life in children born to HIV-1-infected women. Pediatr Pulmonol 2001;31:267-76. |
|
| 80.
| | Paul ME, Chantry CJ, Read JS, et al. Morbidity and mortality during the first two years of life among uninfected children born to human immunodeficiency virus type 1-infected women: the women and infants transmission study. Pediatr Infect Dis J 2005;24:46-56. |
|
| 81.
| | Abrams EJ. Opportunistic infections and other clinical manifestations of HIV disease in children. Pediatr Clin North AM 2000;47:79-108. |
|
| 82.
| | Gesner M, Desiderio D, Kim M, et al. Streptococcus pneumoniae in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 1994;13:697-703. |
|
| 83.
| | Molyneux EM, Tembo M, Kayira K, et al. The effect of HIV infection on paediatric bacterial meningitis in Blantyre, Malawi. Arch Dis Child 2003;88:1112-8. |
|
| 84.
| | Madhi SA, Madhi A, Petersen K, et al. Impact of human immunodeficiency virus type 1 infection on the epidemiology and outcome of bacterial meningitis in South African children. Int J Infect Dis 2001;5:119-25. |
|
| 85.
| | McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002;346:429-37. |
|
| 86.
| | Zar HJ, Tannenbaum E, Hanslo D, et al. Sputum induction as a diagnostic tool for community-acquired pneumonia in infants and young children from a high HIV prevalence area. Pediatr Pulmonol 2003;36:58-62. |
|
| 87.
| | Selwyn PA, Pumerantz AS, Durante A, et al. Clinical predictors of Pneumocystis carinii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. AIDS 1998;12:885-93. |
|
| 88.
| | Sheikh S, Madiraju K, Steiner P, et al. Bronchiectasis in pediatric AIDS. Chest 1997;112:1202-7. |
|
| 89.
| | Midulla F, Strappini P, Sandstrom T, et al. Cellular and noncellular components of bronchoalveolar lavage fluid in HIV-1-infected children with radiological evidence of interstitial lung damage. Pediatr Pulmonol 2001;31:205-13. |
|
| 90.
| | American Academy of Pediatrics. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Elk Grove Village, IL;2006. |
|
| 91.
| | CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR-8). Available at http://www.cdc.gov/mmwr/pdf/rr/ rr4608.pdf. Accessed June 13, 2009. |
|
| 92.
| | Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virusinfected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25:920-9. |
|
| 93.
| | Madhi SA, Ramasamy N, Bessellar TG, et al. Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr Infect Dis J 2002;21:291-7. |
|
| 94.
| | Mulenga V, Ford D, Walker AS, et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 2007;21:77-84. |
|
| 95.
| | Hughes WT, Dankner WM, Yogev R, et al. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis 2005;40:136-45. |
|
| 96.
| | Bobat R, Coovadia H, Stephen C, et al. Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial. Lancet 2005;366:1862-7. |
|
| 97.
| | Irlam JH, Visser ME, Rollins N, et al. Micronutrient supplementation in children and adults with HIV infection. Cochrane Database Syst Rev 2005;Oct 19(4):CD003650. |
|
| 98.
| | CDC. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR 1994;43:1-19. |
|
| 99.
| | Sáez-Llorens X, McCracken GH, Jr. Bacterial meningitis in children. Lancet 2003;361:2139-48. |
|
| 100.
| | Martínez-Aguilar G, Hammerman WA, Mason EO, Jr, et al. Clindamycin treatment of invasive infections caused by communityacquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003;22:593-8. |
|
| 101.
| | Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005;40:1785-91. |
|
| 102.
| | Moallem HJ, Garratty G, Wakeham M, et al. Ceftriaxone-related fatal hemolysis in an adolescent with perinatally acquired human immunodeficiency virus infection. J Pediatr 1998;133:279-81. |
|
| 103.
| | Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004;364:1865-71. |
|
| 104.
| | Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004;48:1921-33. |
|
| 105.
| | Wormser GP. Discovery of new infectious diseases-Bartonella species. N Engl J Med 2007;356:2346-7. |
|
| 106.
| | Slater LN, Welch DF. Bartonella, including cat-scratch disease. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone; 2005. |
|
| 107.
| | Koehler JE, Quinn FD, Berger TG, et al. Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis. N Engl J Med 1992;327:1625-31. |
|
| 108.
| | Spach DH, Koehler JE. Bartonella-associated infections. Infect Dis Clin North Am 1998;12:137-55. |
|
| 109.
| | American Academy of Pediatrics. Cat-scratch disease. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006. |
|
| 110.
| | Reynolds MG, Holman RC, Curns AT, et al. Epidemiology of catscratch disease hospitalizations among children in the United States. Pediatr Infect Dis J 2005;24:700-4. |
|
| 111.
| | Chomel BB, Kasten RW, Floyd-Hawkins K, et al. Experimental transmission of Bartonella henselae by the cat flea. J Clin Microbiol 1996;34:1952-6. |
|
| 112.
| | Zangwill KM, Hamilton DH, Perkins BA, et al. Cat scratch disease in Connecticut. Epidemiology, risk factors, and evaluation of a new diagnostic test. N Engl J Med 1993;329:8-13. |
|
| 113.
| | Carithers HA. Cat-scratch disease. An overview based on a study of 1,200 patients. Am J Dis Child 1985;139:1124-33. |
|
| 114.
| | Jackson LA, Perkins BA, Wenger JD. Cat scratch disease in the United States: an analysis of three national databases. Am J Public Health 1993;83:1707-11. |
|
| 115.
| | Massei F, Gori L, Macchia P, et al. The expanded spectrum of bartonellosis in children. Infect Dis Clin North Am 2005;19:691-711. |
|
| 116.
| | Resto-Ruiz S, Burgess A, Anderson BE. The role of the host immune response in pathogenesis of Bartonella henselae. DNA Cell Biol 2003;22:431-40. |
|
| 117.
| | Myers SA, Prose NS, Garcia JA, et al. Bacillary angiomatosis in a child undergoing chemotherapy. J Pediatr 1992;121:574-8. |
|
| 118.
| | Tappero JW, Koehler JE, Berger TG, et al. Bacillary angiomatosis and bacillary splenitis in immunocompetent adults. Ann Intern Med 1993;118:363-5. |
|
| 119.
| | Koehler JE, Glaser CA, Tappero JW. Rochalimaea henselae infection. A new zoonosis with the domestic cat as reservoir. JAMA 1994;271:531-5. |
|
| 120.
| | Koehler JE. Bartonellosis. In: Dolin R, Masur H, Saag MS, eds. AIDS therapy. 2nd ed. New York, NY: Churchill Livingstone; 2003: 491-7. |
|
| 121.
| | Koehler JE, Sanchez MA, Tye S, et al. Prevalence of Bartonella infection among human immunodeficiency virus-infected patients with fever. Clin Infect Dis 2003;27:559-66. Vol. 58 / RR-11 Recommendations and Reports 103 |
|
| 122.
| | Regnery RL, Childs JE, Koehler JE. Infections associated with Bartonella species in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(Suppl 1):S94-8. |
|
| 123.
| | Gerber MA. Bartonella species (cat-scratch disease, bacillary angiomatosis, bacillary peliosis). In: Long SS, Pickering LK, Prober CG, eds. Principles and practice of pediatric infectious diseases. 2nd ed. Orlando, FL: Churchill Livingstone; 2003. |
|
| 124.
| | Bass JW, Vincent J, Person DA. The expanding spectrum of Bartonella/i> infections: II. Cat-scratch disease. Pediatr Infect Dis J 1997;16:163-79. |
|
| 125.
| | Sander A, Penno S. Semiquantitative species-specific detection of Bartonella henselae and Bartonella quintana by PCR-enzyme immunoassay. J Clin Microbiol 1999;37:3097-101. |
|
| 126.
| | Matar GM, Koehler JE, Malcolm G, et al. Identification of Bartonella species directly in clinical specimens by PCR-restriction fragment length polymorphism analysis of a 16S rRNA gene fragment. J Clin Microbiol 1999;37:4045-7. |
|
| 127.
| | Regnery R, Tappero J. Unraveling mysteries associated with cat-scratch disease, bacillary angiomatosis, and related syndromes. Emerg Infect Dis 1995;1:16-21. |
|
| 128.
| | Bass JW, Freitas BC, Freitas AD, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998;17:447-52. |
|
| 129.
| | Guerra LG, Neira CJ, Boman D, et al. Rapid response of AIDSrelated bacillary angiomatosis to azithromycin. Clin Infect Dis 1993;17:264-6. |
|
| 130.
| | Masur H. Management of opportunistic infections associated with human immunodeficiency virus infection. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005: 1679-1706. |
|
| 131.
| | Gouriet F, Lepidi H, Habib G, et al. From cat scratch disease to endocarditis, the possible natural history of Bartonella henselae infection. BMC Infect Dis 2007;7(Apr 18):30. |
|
| 132.
| | Conrad DA. Treatment of cat-scratch disease. Curr Opin Pediatr 2001;13:56-9. |
|
| 133.
| | Sheffield JS, Sanchez PJ, Morris G, et al. Congenital syphilis after maternal treatment for syphilis during pregnancy. Am J Obstet Gynecol 2002;186:569-73. |
|
| 134.
| | Alexander JM, Sheffield JS, Sanchez PJ, et al. Efficacy of treatment for syphilis in pregnancy. Obstet Gynecol 1999;93:5-8. |
|
| 135.
| | CDC. Sexually transmitted disease surveillance, 2005. Atlanta, GA: U.S. Department of Health and Human Services. November 2006. Available at http://www.cdc.gov/std/stats05/05pdf/2005-exordium.pdf. |
|
| 136.
| | Sison CG, Ostrea EM, Reyes MP, et al. The resurgence of congenital syphilis: a cocaine-related problem. J Pediatr 1997;130:289-92. |
|
| 137.
| | Schulte JM, Burkham S, Hamaker D, et al. Syphilis among HIVinfected mothers and their infants in Texas from 1988 to 1994. Sex Transm Dis 2001;28:315-20. |
|
| 138.
| | Lee MJ, Hallmark RJ, Frenkel LM, et al. Maternal syphilis and vertical perinatal transmission of human immunodeficiency virus type-1 infection. Int J Gynaecol Obstet 1998;63:247-52. |
|
| 139.
| | Mwapasa V, Rogerson SJ, Kwiek JJ, et al. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS 2006;20:1869-77. |
|
| 140.
| | Vermund SH, Wilson CM, Rogers AS, et al. Sexually transmitted infections among HIV infected and HIV uninfected high-risk youth in the REACH study. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health 2001;29(3 Suppl):49-56. |
|
| 141.
| | Blocker ME, Levine WC, St Louis ME. HIV prevalence in patients with syphilis, United States. Sex Transm Dis 2000;27:53-9. |
|
| 142.
| | Singh R, McCloskey J. Syphilis in pregnancy. Venereology 2001:14:121-31. |
|
| 143.
| | Michelow IC, Wendel GD Jr, Norgard MV, et al. Central nervous system infection in congenital syphilis. N Engl J Med 2002;346:1792-8. |
|
| 144.
| | Glaser JH. Centers for Disease Control and Prevention guidelines for congenital syphilis. J Pediatr 1996;129:488-90. |
|
| 145.
| | CDC. Symptomatic early neurosyphilis among HIV-positive men who have sex with men-four cities, United States, January 2002-June 2004. MMWR 2007;56:625-8. |
|
| 146.
| | Pope V. Use of treponemal tests to screen for syphilis. Infect Med 2004;21:399-404. |
|
| 147.
| | Juardo R, Campbell J, Martin PD. Prozone phenomenon in secondary syphilis. Has its time arrived? Arch Intern Med 1993;153:2496-8. |
|
| 148.
| | CDC. Congenital syphilis-United States, 2002. MMWR 2004;53:716-9. |
|
| 149.
| | Beltrami J, Berman S. Congenital syphilis: a persisting sentinel public health event. Sex Transm Dis 2006;33:675-6. |
|
| 150.
| | Kamb ML, Fishbein M, Douglas JM, Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 1998;280:1161-7. |
|
| 151.
| | Fisher JD, Cornman DH, Osborn CY, et al. Clinician-initiated HIV risk reduction intervention for HIV-positive persons: Formative Research, Acceptability, and Fidelity of the Options Project. J Acquir Immune Defic Syndr 2004;37(Suppl 2):S78-87. |
|
| 152.
| | Richardson JL, Milam J, Stoyanoff S, et al. Using patient risk indicators to plan prevention strategies in the clinical care setting. J Acquir Immune Defic Syndr 2004;37(Suppl 2):S88-94. |
|
| 153.
| | CDC, Health Resources and Services Administration, National Institutes of Health, et al. Recommendations for incorporating human immunodeficiency virus (HIV) prevention into the medical care of persons living with HIV. Clin Infect Dis 2004;38:104-21. |
|
| 154.
| | CDC. Sexually transmitted diseases treatment guidelines, 2006. MMWR 2006;55(No. RR-11). |
|
| 155.
| | Yinnon A, Coury-Doniger P, Polito R, et al. Serologic response to treatment of syphilis in patients with HIV infection. Arch Intern Med 1996;156:321-5. |
|
| 156.
| | Moloney G, Branley M, Kotsiou G, et al. Syphilis presenting as scleritis in an HIV-positive man undergoing immune reconstitution. Clin Experiment Ophthalmol 2004;32:526-8. |
|
| 157.
| | CDC. Trends in tuberculosis incidence-United States, 2006. MMWR 2007;56:245-50. |
|
| 158.
| | Nelson LJ, Schneider E, Wells CD, et al. Epidemiology of childhood tuberculosis in the United States, 1993-2001: the need for continued vigilance. Pediatrics 2004;114:333-41. |
|
| 159.
| | Coovadia HM, Jeena P, Wilkinson D. Childhood human immunodeficiency virus and tuberculosis co-infections: reconciling conflicting data. Int J Tuberc Lung Dis 1998;2:844-51. |
|
| 160.
| | Thomas P, Bornschlegel K, Singh TP, et al. Tuberculosis in human immunodeficiency virus-infected and human immunodeficiency virus-exposed children in New York City. The New York City Pediatric Spectrum of HIV Disease Consortium. Pediatr Infect Dis J 2000;19:700-6. |
|
| 161.
| | Shah RS, Tullu MS, Kamat JR. Clinical profile of pediatric HIV infection from India. Arch Med Res 2005;36:24-31. 104 MMWR September 4, 2009 |
|
| 162.
| | Marais BJ, Gie RP, Schaaf HS, et al. The spectrum of disease in children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis 2006;10:732-8. |
|
| 163.
| | Adhikari M, Pillay T, Pillay DG. Tuberculosis in the newborn: an emerging disease. Pediatr Infect Dis J 1997;16:1108-12. |
|
| 164.
| | Pillay T, Strum AW, Khan M, et al. Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 co-infection. Int J Tuberc Lung Dis 2004;8:59-69. |
|
| 165.
| | Bakshi SS, Alvarez D, Hilfer CL, et al. Tuberculosis in human immunodeficiency virus-infected children. A family infection. Am J Dis Child 1993;147:320-4. |
|
| 166.
| | CDC. Human tuberculosis caused by Mycobacterium bovis-New York City, 2001-2004. MMWR 2005;54:605-8. |
|
| 167.
| | LoBue PA, LeClair JJ, Moser KS. Contact investigation for cases of pulmonary Mycobacterium bovis. Int J Tuberc Lung Dis 2004;8: 868-72. |
|
| 168.
| | Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 2006;42:548-58. |
|
| 169.
| | Mukadi YD, Wiktor SZ, Coulibaly IM, et al. Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Cöte d’Ivoire. AIDS 1997;11:1151-8. |
|
| 170.
| | Chintu C, Bhat G, Luo C, et al. Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis. Pediatr Infect Dis J 1993;12:499-504. |
|
| 171.
| | Hoffman ND, Kelly C, Futterman D. Tuberculosis infection in human immunodeficiency virus-positive adolescents and young adults: a New York City cohort. Pediatrics 1996;97:198-203. |
|
| 172.
| | Schaaf HS, Geldenduys A, Gie RP, et al. Culture-positive tuberculosis in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 1998;17:599-604. |
|
| 173.
| | Khouri YF, Mastrucci MT, Hutto C, et al. Mycobacterium tuberculosis in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 1992;11:950-5. |
|
| 174.
| | Chan SP, Birnbaum J, Rao M, et al. Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1996;15:443-7. |
|
| 175.
| | Starke JR. New concepts in childhood tuberculosis. Curr Opin Pediatr 2007;19:306-13. |
|
| 176.
| | Maunatlala C, Alexander H, Williams KL, et al. Reproducibility of an INF-γ release assay and concordance with tuberculin skin tests in people living with HIV. Int J Tuberc Lung Dis 2007; 11 (Supplement 1): S 74. Int J Tuberc Lung Dis 2007;11(Suppl 1):S74. |
|
| 177.
| | Hesseling AC, Mandalakas AM, Chegou N, et al. The impact of M. tuberculosis,/i> exposure, age and HIV infection on T-cell assays to detect M. tuberculosis infection. Int J Tuberc Lung Dis 2007;11 (Suppl 1):S225. |
|
| 178.
| | Starke JR. Diagnosis of tuberculosis in children. Pediatr Infect Dis J 2000;19:1095-6. |
|
| 179.
| | Pomputius WF, 3rd, Rost J, Dennehy PH, et al. Standardization of gastric aspirate technique improves yield in the diagnosis of tuberculosis in children. Pediatr Infect Dis J 1997;16:222-6. |
|
| 180.
| | Iriso R, Mudido PM, Karamagi C, et al. The diagnosis of childhood tuberculosis in an HIV-endemic setting and the use of induced sputum. Int J Tuberc Lung Dis 2005;9:716-26. |
|
| 181.
| | Zar HJ, Hanslo D, Apolles P, et al. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005;365:130-4. |
|
| 182.
| | Owens S, Abdel-Rahman IE, Balyejusa S, et al. Nasopharyngeal aspiration for diagnosis of pulmonary tuberculosis. Arch Dis Child 2007;92:693-6. |
|
| 183.
| | Delacourt C, Poveda JD, Chureau C, et al. Use of polymerase chain reaction for improved diagnosis of tuberculosis in children. J Pediatr 1995;126(5 Pt 1):703-9. |
|
| 184.
| | Pierre C, Olivier C, Lecossier D, et al. Diagnosis of primary tuberculosis in children by amplification and detection of mycobacterial DNA. Am Rev Respir Dis 1993;147:420-4. |
|
| 185.
| | Smith K, Starke J, Eisenach K, et al. Detection of Mycobacterium tuberculosis in clinical specimens from children using a polymerase chain reaction. Pediatrics 1996;97:155-60. |
|
| 186.
| | World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva. WHO/HTM/TB/2006.371. 2006. |
|
| 187.
| | Schaaf HS, Gie RP, Beyers N, et al. Primary drug-resistant tuberculosis in children. Int J Tuberc Lung Dis 2000;4:1149-55. |
|
| 188.
| | Schaaf HS, Gie RP, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002;109:765-71. |
|
| 189.
| | World Health Organization. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007;82:193-6. |
|
| 190.
| | Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007;334:136. |
|
| 191.
| | CDC. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycinbased regimens. MMWR 2002;51:214-5. |
|
| 192.
| | Starke JR, Correa AG. Management of mycobacterial infection and disease in children. Pediatr Infect Dis J 1995;14:455-69. |
|
| 193.
| | World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, Switzerland: (WHO/HTM/TB/2006.361). 2006. |
|
| 194.
| | Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. N Engl J Med 2007;356:656-9. |
|
| 195.
| | CDC. Extensively drug-resistant tuberculosis-United States, 1993- 2006. MMWR 2007;56:250-3. |
|
| 196.
| | Palusci VJ, O’Hare D, Lawrence RM. Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children. Pediatr Infect Dis J 1995;14:144-8. |
|
| 197.
| | Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-61. |
|
| 198.
| | Wendel KA, Alwood KS, Gachuhi R, et al. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001;120:193-7. |
|
| 199.
| | Chien JW, Johnson JL. Paradoxical reactions in HIV and pulmonary TB. Chest 1998;114:933-6. |
|
| 200.
| | Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviralinduced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis 2007;11:417-23. |
|
| 201.
| | Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/ IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416. |
|
| 202.
| | Perez Mato S, van Dyke RB. Pulmonary infections in children with HIV infection. Semin Respir Infect 2002;17:33-46. Vol. 58 / RR-11 Recommendations and Reports 105 |
|
| 203.
| | Reed C, von Reyn CF, Chamblee S, et al. Environmental risk factors for infection with Mycobacterium avium complex. Am J Epidemiol 2006;164:32-40. |
|
| 204.
| | Peacock KH, Lewis L, Lavoie S. Erosive mediastinal lymphadenitis associated with Mycobacterium avium infection in a pediatric acquired immunodeficiency syndrome patient. Pediatr Infect Dis J 2000;19:576-8. |
|
| 205.
| | Hartmann P, Plum G. Immunological defense mechanisms in tuberculosis and MAC-infection. Diagn Microbiol Infect Dis 1999; 34:147-52. |
|
| 206.
| | Keller C, Kirkpatrick S, Lee K, et al. Disseminated Mycobacterium avium complex presenting as hematochezia in an infant with rapidly progressive acquired immunodeficiency syndrome. Pediatr Infect Dis J 1996;15:713-5. |
|
| 207.
| | Wong DA, Yip PC, Cheung DT, et al. Simple and rational approach to the identification of Mycobacterium tuberculosis, Mycobacterium avium complex species, and other commonly isolated mycobacteria. J Clin Microbiol 2001;39:3768-71. |
|
| 208.
| | Lewis LL, Butler KM, Husson RN, et al. Defining the population of human immunodeficiency virus-infected children at risk for Mycobacterium avium-intracellulare infection. J Pediatr 1992;121:677-83. |
|
| 209.
| | Rutstein R, Cobb P, McGowan K, et al. Mycobacterium avium intracellulare complex infection in HIV-infected children AIDS 1993;7: 507-12. |
|
| 210.
| | Smith JA, Mueller BU, Nussenblatt RB, Whitcup SM. Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Am J Ophthalmol 1999;127:164-9. |
|
| 211.
| | Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998;351:252-5. |
|
| 212.
| | Phillips P, Chan K, Hogg R, et al. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program. Clin Infect Dis 2002;34:371-8. |
|
| 213.
| | Steenhoff AP, Wood SM, Shah SS, et al. Cutaneous Mycobacterium avium complex infection as a manifestation of the immune reconstitution syndrome in a human immunodeficiency virus-infected child. Pediatr Infect Dis J 2007;26:755-7. |
|
| 214.
| | Long SS. Principles and practice of pediatric infectious diseases. 2nd ed. Orlando, FL: Churchill Livingstone; 2003. |
|
| 215.
| | Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26: 781-803. |
|
| 216.
| | Herbrecht R, Auvrignon A, Andrès E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001;20:77-82. |
|
| 217.
| | Shetty D, Giri N, Gonzalez CE, et al. Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1997;16:216-21. |
|
| 218.
| | Drut R, Anderson V, Greco MA, et al. Opportunistic infections in pediatric HIV infection: a study of 74 autopsy cases from Latin America. The Latin American AIDS Pathology Study Group. Pediatr Pathol Lab Med 1997;17:569-76. |
|
| 219.
| | Reik RA, Rodriguez MM, Hensley GT. Infections in children with human immunodeficiency virus/acquired immunodeficiency syndrome: an autopsy study of 30 cases in south Florida, 1990-1993. Pediatr Pathol Lab Med 1995;15:269-81. |
|
| 220.
| | Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324:654-62. |
|
| 221.
| | Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32. |
|
| 222.
| | Lortholary O, Meyohas MC, Dupont B, et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med 1993;95:177-87. |
|
| 223.
| | Walsh TJ, Gonzalez C, Lyman CA, et al. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1996:11:187-290. |
|
| 224.
| | Roilides E, Holmes A, Blake C, et al. Defective antifungal activity of monocyte-derived macrophages from human immunodeficiency virus-infected children against Aspergillus fumigatus. J Infect Dis 1993;168:1562-5. |
|
| 225.
| | Muller FM, Trusen A, Weig M. Clinical manifestations and diagnosis of invasive aspergillosis in immunocompromised children. Eur J Pediatr 2002;161:563-74. |
|
| 226.
| | Domachowske JB. Pediatric human immunodeficiency virus infection. Clin Microbiol Rev 1996;9:448-68. |
|
| 227.
| | Wright M, Fikrig S, Haller JO. Aspergillosis in children with acquired immune deficiency. Pediatr Radiol 1993;23:492-4. |
|
| 228.
| | Leibovitz E, Rigaud M, Chandwani S, et al. Disseminated fungal infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1991;10:888-94. |
|
| 229.
| | CDC. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. The most recent information is available at http://aidsinfo.nih.gov. MMWR 2004;53 (No. RR-15). |
|
| 230.
| | Sulahian A, Tabouret M, Ribaud P, et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis 1996;15:139-45. |
|
| 231.
| | Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:1898-906. |
|
| 232.
| | Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9. |
|
| 233.
| | Steinbach WJ. Pediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J 2005;24:358-64. |
|
| 234.
| | Thomas KE, Owens CM, Veys PA, et al. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr Radiol 2003;33:453-60. |
|
| 235.
| | Allan BT, Patton D, Ramsey NK, et al. Pulmonary fungal infections after bone marrow transplantation. Pediatr Radiol 1988;18:118-22. |
|
| 236.
| | Taccone A, Occhi M, Garaventa A, et al. CT of invasive pulmonary aspergillosis in children with cancer. Pediatr Radiol 1993;23:177-80. |
|
| 237.
| | Allo MD, Miller J, Townsend T, et al. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 1987;317:1105-8. |
|
| 238.
| | Bryce EA, Walker M, Scharf S, et al. An outbreak of cutaneous aspergillosis in a tertiary-care hospital. Infect Control Hosp Epidemiol 1996;17:170-2. 106 MMWR September 4, 2009 |
|
| 239.
| | James MJ, Lasker BA, McNeil MM, et al. Use of a repetitive DNA probe to type clinical and environmental isolates of Aspergillus flavus from a cluster of cutaneous infections in a neonatal intensive care unit. J Clin Microbiol 2000;38:3612-8. |
|
| 240.
| | Ruutu P, Valtonen V, Tiitanen L, et al. An outbreak of invasive aspergillosis in a haematologic unit. Scand J Infect Dis 1987;19:347-51. |
|
| 241.
| | Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002;34:780-9. |
|
| 242.
| | Opal S, Asp AA, Cannady PB, et al. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 1986;153:634-7. |
|
| 243.
| | Morgenstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999;105:901-11. |
|
| 244.
| | Rousey SR, Russler S, Gottlieb M, et al. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991;91:484-92. |
|
| 245.
| | Siwek GT, Pfaller MA, Polgreen PM, et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006;55:209-12. |
|
| 246.
| | Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15. |
|
| 247.
| | Cesaro S, Strugo L, Alaggio R, et al. Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer 2003;11:722-7. |
|
| 248.
| | Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am 2005;52:895-915. |
|
| 249.
| | Blyth CC, Palasanthiran P, O' Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics 2007;119:772-84. |
|
| 250.
| | Pannaraj PS, Walsh TJ, Baker CJ. Advances in antifungal therapy. Pediatr Infect Dis J 2005;24:921-2. |
|
| 251.
| | Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-8. |
|
| 252.
| | Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007;67:269-98. |
|
| 253.
| | Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004;48:2166-72. |
|
| 254.
| | Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999;18:702-8. |
|
| 255.
| | Sambatakou H, Denning DW. Invasive pulmonary aspergillosis transformed into fatal mucous impaction by immune reconstitution in an AIDS patient. Eur J Clin Microbiol Infect Dis 2005;24:628-33. |
|
| 256.
| | Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49:4536-45. |
|
| 257.
| | Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802. |
|
| 258.
| | Merlin E, Galambrun C, Ribaud P, et al. Efficacy and safety of caspofungin therapy in children with invasive fungal infections. Pediatr Infect Dis J 2006;25:1186-8. |
|
| 259.
| | Cesaro S, Giacchino M, Locatelli F, et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis 2007;7(Apr 18):28. |
|
| 260.
| | Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006;81:320-6. |
|
| 261.
| | Johnson MD, Perfect JR. Combination antifungal therapy: what can and should we expect? Bone Marrow Transplant 2007;40:297-306. |
|
| 262.
| | Baddley JW, Pappas PG. Combination antifungal therapy for the treatment of invasive yeast and mold infections. Curr Infect Dis Rep 2007;9:448-56. |
|
| 263.
| | Raad II, Hanna HA, Boktour M, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008;22:496-503. |
|
| 264.
| | Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53:337-49. |
|
| 265.
| | Karp JE, Burch PA, Merz WG. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 1988;85:203-6. |
|
| 266.
| | Chiou CC, Groll AH, Gonzalez CE, et al. Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: clinical manifestations and risk factors. Pediatr Infect Dis J 2000;19:729-34. |
|
| 267.
| | Walsh TJ, Gonzalez C, Roilides E, et al. Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin Infect Dis 1995;20:900-6. |
|
| 268.
| | Chiou CC, Groll AH, Mavrogiorgos N, et al. Esophageal candidiasis in human immunodeficiency virus-infected pediatric patients after the introduction of highly active antiretroviral therapy. Pediatr Infect Dis J 2002;21:388-92. |
|
| 269.
| | Gonzalez CE, Venzon D, Lee S, et al. Risk factors for fungemia in children infected with human immunodeficiency virus: a case-control study. Clin Infect Dis 1996;23:515-21. |
|
| 270.
| | Krcmery V, Augustinova A, Babelova O, et al. Fungal resistance in Cambodian children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2006;25:470. |
|
| 271.
| | Muller FM, Groll AH, Walsh TJ. Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus. Eur J Pediatr 1999;158:187-99. |
|
| 272.
| | Stevens D. Diagnosis of fungal infections: current status. J Antimicrob Chemother 2002;49(Suppl 1):11-9. |
|
| 273.
| | Sigmundsdottir G, Larsson L, Wiebe T, et al. Clinical experience of urine D-arabinitol/L-arabinitol ratio in the early diagnosis of invasive candidiasis in paediatric high risk populations. Scand J Infect Dis 2007;39:146-51. |
|
| 274.
| | Yeo SF, Huie S, Sofair AN, et al. Measurement of serum D-arabinitol/ creatinine ratios for initial diagnosis and for predicting outcome in an unselected, population-based sample of patients with Candida fungemia. J Clin Microbiol 2006;44:3894-9. |
|
| 275.
| | Verduyn Lunel FM, Voss A, Kuijper EJ, et al. Detection of the Candida antigen mannan in cerebrospinal fluid specimens from patients suspected of having Candida meningitis. J Clin Microbiol 2004;42:867-70. Vol. 58 / RR-11 Recommendations and Reports 107 |
|
| 276.
| | Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654-9. |
|
| 277.
| | Klingspor L, Jalal S. Molecular detection and identification of Candida and Aspergillus spp. from clinical samples using real-time PCR. Clin Microbiol Infect 2006;12:745-53. |
|
| 278.
| | Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 2006: July 19;3:C003940. |
|
| 279.
| | Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:662-78. |
|
| 280.
| | Pelletier R, Peter J, Antin C, et al. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virusinfected children: in vitro and clinical correlations. J Clin Microbiol 2000;38:1563-8. |
|
| 281.
| | Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1993;6:1311-6. |
|
| 282.
| | Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997;24:1204-7. |
|
| 283.
| | Goins RA, Ascher D, Waecker N, et al. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. Pediatr Infect Dis J 2002;21:1165-7. |
|
| 284.
| | Phillips P, de Beule K, Frechette G, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS Clin Infect Dis 1998;26:1368-73. |
|
| 285.
| | Wilcox CM, Darouiche RO, Laine L, et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J infect Dis 1997;176:227-32. |
|
| 286.
| | Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9. |
|
| 287.
| | Walsh TJ. Echinocandins-an advance in the primary treatment of invasive candidiasis N Engl J Med 2002;347:2070-2. |
|
| 288.
| | Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36:1445-57. |
|
| 289.
| | Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000; 30:653-7. |
|
| 290.
| | Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 1994;13:325-9. |
|
| 291.
| | de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, doubleblind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39:842-9. |
|
| 292.
| | Krause DS, Simjee AE, van Rensburg C, et al. A randomized, doubleblind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39:770-5. |
|
| 293.
| | Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized doubleblind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294-9. |
|
| 294.
| | Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23:1093-7. |
|
| 295.
| | Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49:3317-24. |
|
| 296.
| | Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25:1110-5. |
|
| 297.
| | Tabata K, Katashima M, Kawamura A, et al. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol Pharm Bull 2006;29:1706-11. |
|
| 298.
| | Benjamin DK, Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50:632-8. |
|
| 299.
| | Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8. |
|
| 300.
| | Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7. |
|
| 301.
| | Nacher M, Vantilcke V, Huber F, et al. Increased incidence of mucosal candidiasis after HAART initiation: a benign form of immune reconstitution disease? AIDS 2007;21:2534-6. |
|
| 302.
| | Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002;46:2554-63. |
|
| 303.
| | Phillips P, Zemcov J, Mahmood W, et al. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996;10:1369-76. |
|
| 304.
| | Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998;26:556-65. |
|
| 305.
| | Skiest D, Vazquez J, Anstead G, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007;44:607-14. |
|
| 306.
| | Zaoutis TE, Benjamin DK, Steinbach WJ. Antifungal treatment in pediatric patients. Drug Resist Updat 2005;8:235-45. |
|
| 307.
| | Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007;51:812-8. |
|
| 308.
| | Lake DE, Kunzweiler J, Beer M, et al. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy 1996;42:308-14. |
|
| 309.
| | Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8. |
|
| 310.
| | Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997; 41:1944-8. |
|
| 311.
| | Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005;24:167-74. |
|
| 312.
| | Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71. 108 MMWR September 4, 2009 |
|
| 313.
| | Linden P, Lee L, Walsh TJ. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections. Pharmacotherapy 1999;19:1261-8. |
|
| 314.
| | Tollemar J, Klingspor L, Ringdén O. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. Clin Microbiol Infect 2001;7(Suppl 2):68-79. |
|
| 315.
| | Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005;41:1473-80. |
|
| 316.
| | DiCaudo DJ. Coccidioidomycosis: a review and update. J Am Acad Dermatol 2006;55:929-42. |
|
| 317.
| | Crum NF, Lederman ER, Stafford CM, et al. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore) 2004;83:149-75. |
|
| 318.
| | Stagliano D, Epstein J, Hickey P. Fomite-transmitted coccidioidomycosis in an immunocompromised child. Pediatr Infect Dis J 2007;26:454-6. |
|
| 319.
| | Ampel NM, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med 1993;94:235-40. |
|
| 320.
| | Ampel NM. Coccidioidomycosis in persons infected with HIV-1. Ann N Y Acad Sci 2007: 111:336-42. |
|
| 321.
| | Ampel NM. Coccidioidomycosis among persons with human immunodeficiency virus infection in the era of highly active antiretroviral therapy (HAART). Semin Respir Infect 2001;16:257-62. |
|
| 322.
| | Ampel NM. Coccidioidomycosis in persons infected with HIV type 1. Clin Infect Dis 2005;41:1174-8. |
|
| 323.
| | Woods CW, McRill C, Plikaytis BD, et al. Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. J Infect Dis 2000;181:1428-34. |
|
| 324.
| | Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:658-61. |
|
| 325.
| | Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000;133:676-86. |
|
| 326.
| | Saitoh A, Homans J, Kovacs A. Fluconazole treatment of coccidioidal meningitis in children: two case reports and a review of the literature. Pediatr Infect Dis J 2000;19:1204-8. |
|
| 327.
| | Huang YW, Chang CC, Sun HY, et al. Primary adrenal insufficiency in patients with acquired immunodeficiency syndrome: report of four cases. J Microbiol Immunol Infect 2004;37:250-3. |
|
| 328.
| | Anstead GM, Corcoran G, Lewis J, et al. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005;40:1770-6. |
|
| 329.
| | Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother 2004;48:2341. |
|
| 330.
| | Prabhu RM, Bonnell M, Currier BL, et al. Successful treatment of disseminated nonmeningeal coccidioidomycosis with voriconazole. Clin Infect Dis 2004;39:e74-7. |
|
| 331.
| | Hsue G, Napier JT, Prince RA, et al. Treatment of meningeal coccidioidomycosis with caspofungin. J Antimicrob Chemother 2004; 54:292-4. |
|
| 332.
| | Antony S. Use of the echinocandins (caspofungin) in the treatment of disseminated coccidioidomycosis in a renal transplant recipient. Clin Infect Dis 2004;39:879-80. |
|
| 333.
| | Park DW, Sohn JW, Cheong HJ, et al. Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole. BMC Infect Dis 2006: Feb 15;6:26. |
|
| 334.
| | Kuberski TT, Servi RJ, Rubin PJ. Successful treatment of a critically ill patient with disseminated coccidioidomycosis, using adjunctive interferon-gamma. Clin Infect Dis 2004;38:910-2. |
|
| 335.
| | Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005;41:1217-23. |
|
| 336.
| | Carmichael JK. Coccidioidomycosis in HIV-infected persons. Clin Infect Dis 2006;42:1059; author reply 1059-60. |
|
| 337.
| | Mathew G, Smedema M, Wheat LJ, et al. Relapse of coccidioidomycosis despite immune reconstitution after fluconazole secondary prophylaxis in a patient with AIDS. Mycoses 2003;46:42-4. |
|
| 338.
| | Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996;124:305-10. |
|
| 339.
| | Leggiadro RJ, Kline MW, Hughes WT. Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1991;10:658-62. |
|
| 340.
| | Gonzalez CE, Shetty D, Lewis LL, et al. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996;15:796-800. |
|
| 341.
| | Abadi J, Nachman S KA, Pirofski L. Cryptococcosis in children with AIDS. Clin Infect Dis 1999;28:309-13. |
|
| 342.
| | Mirza S, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003;36:789-94. |
|
| 343.
| | Gumbo T, Kadzirange G, Mielke J, et al. Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2002;21:54-6. |
|
| 344.
| | Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321: 794-9. |
|
| 345.
| | Currie BP, Freundlich LF, Soto MA, et al. False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis. J Clin Microbiol 1993;31:2519-22. |
|
| 346.
| | Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005;43:2163-7. |
|
| 347.
| | Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001;107:E66. |
|
| 348.
| | Chang LW, Phipps WT, Kennedy GE, et al. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005;Jul 20:CD004773. |
|
| 349.
| | Shelburne SA, Darcourt J, White AC, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:1049-52. |
|
| 350.
| | Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005;194. |
|
| 351.
| | Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for lesscommon, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31. Vol. 58 / RR-11 Recommendations and Reports 109 |
|
| 352.
| | Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005;56:745-55. |
|
| 353.
| | Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979;301:126-31. |
|
| 354.
| | van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21. |
|
| 355.
| | Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-8. |
|
| 356.
| | Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-7. |
|
| 357.
| | Dromer F, Mathoulin-Pélissier S, Launay O, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLOS Med 2007;4:e21. |
|
| 358.
| | Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11:1463-71. |
|
| 359.
| | Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-5. |
|
| 360.
| | Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998;26:1362-6. |
|
| 361.
| | Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326:83-9. |
|
| 362.
| | Bicanic T, Harrison T, Niepieklo A, et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006;43:1069-73. |
|
| 363.
| | Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45:76-80. |
|
| 364.
| | Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28:291-6. |
|
| 365.
| | Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000;30:47-54. |
|
| 366.
| | Newton PN, Thai le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002;35:769-72. |
|
| 367.
| | Powderly WG, Cloud GA, Dismukes WE, et al. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994;18:789-92. |
|
| 368.
| | Aberg JA, Watson J, Segal M, et al. Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease. HIV Clin Trials 2000;1:1-6. |
|
| 369.
| | Lortholary O, Fontanet A, Mémain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIVassociated cryptococcosis in France. AIDS 2005;19:1043-9. |
|
| 370.
| | Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005;51:e289-97. |
|
| 371.
| | Lesho E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther 2006;4: 469-78. |
|
| 372.
| | Lortholary O. Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries. Clin Infect Dis 2007;45:81-3. |
|
| 373.
| | Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991;324:580-4. |
|
| 374.
| | Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992;326:793-8. |
|
| 375.
| | Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002;137:239-50. |
|
| 376.
| | Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003;36:1329-31. |
|
| 377.
| | Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004;38:565-71. |
|
| 378.
| | Whitt SP, Koch GA, Fender B, et al. Histoplasmosis in pregnancy: case series and report of transplacental transmission. Arch Intern Med 2004;164:454-8. |
|
| 379.
| | Wheat LJ, Chetchotisakd P, Williams B, et al. Factors associated with severe manifestations of histoplasmosis in AIDS. Clin Infect Dis 2000;30:877-81. |
|
| 380.
| | Schutze GE, Tucker NC, Jacobs RF. Histoplasmosis and perinatal human immunodeficiency virus. Pediatr Infect Dis J 1992;11:501-2. |
|
| 381.
| | Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45:807-25. |
|
| 382.
| | Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis 2005;40: 844-52. |
|
| 383.
| | Saidinejad M, Burns MM, Harper MB. Disseminated histoplasmosis in a nonendemic area. Pediatr Infect Dis J 2004;23:781-2. |
|
| 384.
| | Byers M, Feldman S, Edwards J. Disseminated histoplasmosis as the acquired immunodeficiency syndrome-defining illness in an infant. Pediatr Infect Dis J 1992;11:127-8. 110 MMWR September 4, 2009 |
|
| 385.
| | Pillay T, Pillay DG, Bramdev A. Disseminated histoplasmosis in a human immunodeficiency virus-infected African child. Pediatr Infect Dis J 1997;16:417-8. |
|
| 386.
| | Odio CM, Navarrete M, Carrillo JM, et al. Disseminated histoplasmosis in infants. Pediatr Infect Dis J 1999;18:1065-8. |
|
| 387.
| | Leggiadro RJ, Barrett FF, Hughes WT. Disseminated histoplasmosis of infancy. Pediatr Infect Dis J 1988;7:799-805. |
|
| 388.
| | Hughes WT. Hematogenous histoplasmosis in the immunocompromised child. J Pediatr 1984;105:569-75. |
|
| 389.
| | Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis 2006;8:128-39. |
|
| 390.
| | Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther 2006;6:1207-21. |
|
| 391.
| | Brandt ME, Warnock DW. Histoplasma, Blastomyces, Coccidioides, and other dimorphic fungi causing systemic mycoses. In Manual of clinical microbiology, 9th ed. P. Murray, ed. 2007;9:1857-65. |
|
| 392.
| | Bialek R, Feucht A, Aepinus C, et al. Evaluation of two nested PCR assays for detection of Histoplasma capsulatum DNA in human tissue. J Clin Microbiol 2002;40:1644-7. |
|
| 393.
| | Tang YM, Li H, Durkin MM, et al. Urine polymerase chain reaction is not as sensitive as urine antigen for the diagnosis of disseminated histoplasmosis. Diagn Microbiol Infect Dis 2006;54:283-7. |
|
| 394.
| | Tobon AM, Agudelo CA, Rosero DS, et al. Disseminated histoplasmosis: a comparative study between patients with acquired immunodeficiency syndrome and non-human immunodeficiency virus-infected individuals. Am J Trop Med Hyg 2005;73:576-82. |
|
| 395.
| | Fojtasek MF, Kleiman MB, Connolly-Stringfield P, et al. The Histoplasma capsulatum antigen assay in disseminated histoplasmosis in children. Pediatr Infect Dis J 1994;13:801-5. |
|
| 396.
| | Lenhart SW, Schafer MP, Singal M, et al. Histoplasmosis-protecting workers at risk. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2004. DHHS (NIOSH) Publication No. 2005-109. Available at http://www.cdc.gov/niosh/docs/2005-109/#a. |
|
| 397.
| | Goldman M, Zackin R, Fichtenbaum CJ, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004;38: 1485-9. |
|
| 398.
| | Dismukes WE, Bradsher RW, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992;93:489-97. |
|
| 399.
| | Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995;98:336-42. |
|
| 400.
| | Wheat LJ, Connolly P, Smedema M, et al. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis 2001;33:1910-3. |
|
| 401.
| | Adderson EE. Histoplasmosis in a pediatric oncology center. J Pediatr 2004;144:100-6. |
|
| 402.
| | Wheat LJ, Connolly-Stringfield P, Blair R, et al. Effect of successful treatment with amphotericin B on Histoplasma capsulatum variety capsulatum polysaccharide antigen levels in patients with AIDS and histoplasmosis. Am J Med 1992;92:153-60. |
|
| 403.
| | Nacher M, Sarazin F, El Guedj M, et al. Increased incidence of disseminated histoplasmosis following highly active antiretroviral therapy initiation. J Acquir Immune Defic Syndr 2006;41:468-70. |
|
| 404.
| | Vargas SL, Hughes WT, Santolaya ME, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001;32:855-61. |
|
| 405.
| | Respaldiza N, Medrano FJ, Medrano AC, et al. High seroprevalence of Pneumocystis infection in Spanish children. Clin Microbiol Infect 2004;10:1029-31. |
|
| 406.
| | Pifer LL, Hughes WT, Stagno S, et al. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978;61:35-41. |
|
| 407.
| | Simonds RJ, Oxtoby MJ, Caldwell MB, et al. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 1993;270:470-3. |
|
| 408.
| | Gibb DM, Davison CF, Holland FJ, et al. Pneumocystis carinii pneumonia in vertically acquired HIV infection in the British Isles. Arch Dis Child 1994;70:241-4. |
|
| 409.
| | Williams AJ, Duong T, McNally LM, et al. Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection. AIDS 2001;15:335-9. |
|
| 410.
| | Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004;10:1713-20. |
|
| 411.
| | Ikeogu MO, Wolf B, Mathe S. Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe. Arch Dis Child 1997;76:124-8. |
|
| 412.
| | Chintu C, Mudenda V, Lucas S, et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002;360:985-90. |
|
| 413.
| | Madhi SA, Cutland C, Ismail K, et al. Ineffectiveness of trimethoprim- sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia. Clin Infect Dis 2002;35:1120-6. |
|
| 414.
| | Hendley JO, Weller TH. Activation and transmission in rats of infection with Pneumocystis. Proc Soc Exp Biol Med 1971;137:1401-4. |
|
| 415.
| | Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis 1982;145:842-8. |
|
| 416.
| | de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007;44:1143-9. |
|
| 417.
| | Hocker B, Wendt C, Nahimana A, et al. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 2005;11:330-2. |
|
| 418.
| | Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 2004;10:1766-73. |
|
| 419.
| | Mortier E, Pouchot J, Bossi P, et al. Maternal-fetal transmission of Pneumocystis carinii in human immunodeficiency virus infection. N Engl J Med 1995;332:825. |
|
| 420.
| | Fatti GL, Zar HJ, Swingier GH. Clinical indicators of Pneumocystis jiroveci pneumonia (PCP) in South African children infected with the human immunodeficiency virus. Int J Infect Dis 2006;10:282-5. |
|
| 421.
| | Podlekareva D, Mocroft A, Dragsted UB, et al. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. J Infect Dis 2006;194:633-41. |
|
| 422.
| | Ng VI, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997;10:401-18. |
|
| 423.
| | Chen A, Zaidi AK, Mueller BU, et al. Pneumocystis carinii presenting as a mediastinal mass in a child with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1999;18:827-31. |
|
| 424.
| | Surve TY, Rathod AD. Role of nasogastric aspirate in HIV-positve children presenting with respiratory symptoms. J Trop Pediatr 2006;52:451-3. |
|
| 425.
| | Chan H, Pifer L, Hughes WT, et al. Comparison of gastric contents to pulmonary aspirates for the cytologic diagnosis of Pneuomcystis carinii pneumonia. J Pediatr 1977;90:243-4. |
|
| 426.
| | Huang L, Morris A, Limper AH, et al. An Official ATS Workshop Summary: Recent advances and future directions in Pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006;3:655-64. |
|
| 427.
| | Lebovitz E, Pollack H, Rigaud M, et al. Polymerase chain reaction is more sensitive than standard cytologic stains in detecting Pneumocystis carinii in bronchoalveolar lavages from human immunodeficiency virus type 1-infected infants and children with pneumonia. Pediatr Infect Dis J 1995;14:714-6. |
|
| 428.
| | Maskell NA, Waine DJ, Lindley A, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 2003;58:594-7. |
|
| 429.
| | Glatman-Freedman A, Ewig JM, Dobroszycki J, et al. Simultaneous Pneumocystis carinii and pneumococcal pneumonia in human immunodeficiency virus-infected children. J Pediatr 1998;132: 169-71. |
|
| 430.
| | Jeena PM, Coovadia HM, Chrystal V. Pneumocystis carinii and cytomegalovirus infections in severely ill, HIV-infected African infants. Ann Trop Paediatr 1996;16:361-8. |
|
| 431.
| | CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. |
|
| 432.
| | Hughes WT, Rivera GK, Schell MJ, et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316:1627-32. |
|
| 433.
| | Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419-26. |
|
| 434.
| | Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim- sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992;117:106-11. |
|
| 435.
| | Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995;332:693-9. |
|
| 436.
| | Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992;327:1842-8. |
|
| 437.
| | Dworkin MS, Williamson J, Jones JL, et al. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virusinfected patients: impact on risk for infectious diseases. Clin Infect Dis 2001;33:393-8. |
|
| 438.
| | Martin JN, Rose DA, Hadley WK, et al. Emergence of trimethoprim- sulfamethoxazole resistance in the AIDS era. J Infect Dis 1999;180: 1809-18. |
|
| 439.
| | Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 2001;32:1608-14. |
|
| 440.
| | El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998;339:1889-95. |
|
| 441.
| | Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 1998;27: 191-204. |
|
| 442.
| | Principi N, Marchisio P, Onorato J, et al. Long-term administration of aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia in infants and children with symptomatic human immunodeficiency virus infection. The Italian Pediatric Collaborative Study Group on Pentamidine. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:158-63. |
|
| 443.
| | Milstone AM, Balakrishnan SL, Foster CB, et al. Failure of intravenous pentamidine prophylaxis to prevent Pneumocystis pneumonia in a pediatric hematopoietic stem cell transplant (HSCT) patient. Pediatr Blood Cancer 2006;47:859-60. |
|
| 444.
| | Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999;340:1301-6. |
|
| 445.
| | Schneider MM, Borleffs JC, Stolk RP, et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 1999;353:201-3. |
|
| 446.
| | Dworkin MS, Hanson DL, Kaplan JE, et al. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis 2000;182:611-5. |
|
| 447.
| | Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001;344:168-74. |
|
| 448.
| | Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001;344:159-67. |
|
| 449.
| | Zar JH, Langdon G, Apolles P, et al. Oral trimethoprim- sulphamethoxazole levels in stable HIV-infected children. S Afr Med J 2006;96:627-9. |
|
| 450.
| | Leoung GS, Mills J, Hopewell PC, et al. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986;105:45-8. |
|
| 451.
| | Mirochnick M, Cooper E, McIntosh K, et al. Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virusinfected children. Antimicrob Agents Chemother 1999;43:2586-91. |
|
| 452.
| | Mills J, Leoung G, Medina I, et al. Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1988;32:1057-60. |
|
| 453.
| | Sleasman JW, Hemenway C, Klein AS, et al. Corticosteroids improve survival of children with AIDS and Pneumocystis carinii pneumonia. Am J Dis Child 1993;147:30-4. |
|
| 454.
| | Bye MR, Cairns-Bazarian AM, Ewig JM. Markedly reduced mortality associated with corticosteroid therapy of Pneumocystis carinii pneumonia in children with acquired immunodeficiency syndrome. Arch Pediatr Adolesc Med 1994;148:638-41. |
|
| 455.
| | McLaughlin GE, Virdee SS, Schleien CL, et al. Effect of corticosteroids on survival of children with acquired immunodeficiency syndrome and Pneumocystis carinii-related respiratory failure. J Pediatr 1995;126 (5 Pt 1):821-4. |
|
| 456.
| | Creery WE, Hashmi A, Hutchison JS, et al. Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome. Pediatr Pulmonol 1997;24: 370-3. |
|
| 457.
| | Marriage S, Underhill H, Nadel S. Use of natural surfactant in an HIV-infected infant with Pneumocystis carinii pneumonia. Intensive Care Med 1995;22:611-2. |
|
| 458.
| | Slater A, Nichani SH, Macrae D, et al. Surfactant adjunctive therapy for Pneumocystis carinii pneumonitis in an infant with acute lymphoblastic leukaemia. Intensive Care Med 1995;21:261-3. |
|
| 459.
| | Schmidt R, Markart P, Ruppert C, et al. Pulmonary surfactant in patients with Pneumocystis pneumonia and acquired immunodeficiency syndrome. Crit Care med 2006;34:2370-6. |
|
| 460.
| | Datta D, Ali SA, Henken EM, et al. Pneumocystis carinii pneumonia: the time course of clinical and radiographic improvement. Chest 2003;124:1820-3. |
|
| 461.
| | Ratnam I, Chiu C, Kandala NB, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006;42:418-27. |
|
| 462.
| | Gutman LT. The use of trimethoprim-sulfamethoxazole in children: a review of adverse reactions and indications. Pediatr Infect Dis J 1984;3:349-57. |
|
| 463.
| | Rieder MJ, King SM, Read S. Adverse reactions to trimethoprim- sulfamethoxazole among children with human immunodeficiency virus infection. Pediatr Infect Dis J 1997;16:1028-31. |
|
| 464.
| | Para MF, Finkelstein D, Becker S, et al. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr 2000;24:337-43. |
|
| 465.
| | Leoung GS, Stanford JF, Giordano MF, et al. Trimethoprim- sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis 2001;184:992-7. |
|
| 466.
| | Goodwin SD. Pneumocystis carinii pneumonia in human immunodeficiency virus-infected infants and children. Pharmacotherapy 1993;13: 640-6. |
|
| 467.
| | Mussini C, Pezzotti P, Antinori A, et al. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis 2003;36:645-51. |
|
| 468.
| | Leav BA, Mackay M, Ward HD. Cryptosporidium species: new insights and old challenges Clin Infect Dis 2003;36:903-8. |
|
| 469.
| | Heijbel H, Slaine K, Seigel B, et al. Outbreak of diarrhea in a day care center with spread to household members: the role of Cryptosporidium. Pediatr Infect Dis J 1987;6:532-5. |
|
| 470.
| | Puech MC, McAnulty JM, Lesjak M, et al. A statewide outbreak of cryptosporidiosis in New South Wales associated with swimming at public pools. Epidemiol Infect 2001;126:389-96. |
|
| 471.
| | Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999;5:607-25. |
|
| 472.
| | Pettoello-Mantoani M, Di Martino L, Dettori G, et al. Asymptomatic carriage of intestinal Cryptosporidium in immunocompetent and immunodeficient children: a prospective study. Pediatr Infect Dis J 1995;14:1042-7. |
|
| 473.
| | Cegielski JP, McKee S, Madden JF, et al. Cryptosporidium, Enterocytozoon, and Cyclospora infections in pediatric and adult patients with diarrhea in Tanzania. Clin Infect Dis 1999;28:314-21. |
|
| 474.
| | Tumwine JK, Kekitiinwa A, Nabukeera N, et al. Cryptosporidium parvum in children with diarrhea in Mulago Hospital, Kampala, Uganda. Am J Trop Med Hyg 2003;68:710-5. |
|
| 475.
| | Huang DB, White AC. An updated review on Cryptosporidium and Giardia. Gastroenterol Clin North Am 2006;35:291-314. |
|
| 476.
| | Chen XM, Keithly JS, Paya CV, et al. Cryptosporidiosis. N Engl J Med 2002;346:1723-31. |
|
| 477.
| | Mathis A. Microsporidia: emerging advances in understanding the basic biology of these unique organisms. Int J Parasitol 2000;30:795-804. |
|
| 478.
| | Hutin YJ, Sombardier MN, Liguory O, et al. Risk factors for intestinal microsporidiosis in patients with human immunodeficiency virus infection: a case-control study. J Infect Dis 1998;178:904-7. |
|
| 479.
| | Newman RD, Sears CL, Moore SR, et al. Longitudinal study of Cryptosporidium infection in children in northeastern Brazil. J Infect Dis 1999;180:167-75. |
|
| 480.
| | Lima AA, Moore SR, Barboza MS Jr, et al. Persistent diarrhea signals a critical period of increased diarrhea burdens and nutritional shortfalls: a prospective cohort study among children in northeastern Brazil. J Infect Dis 2000;181:1643-51. |
|
| 481.
| | Vakil NB, Schwartz SM, Buggy BP, et al. Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee. N Engl J Med 1996;334:19-23. |
|
| 482.
| | Kotler DP, Orenstein JM. Clinical syndromes associated with microsporidiosis. Adv Parasitol 1998: 40:321-49. |
|
| 483.
| | Weber R, Bryan RT, Bishop HS, et al. Threshold of detection of Cryptosporidium oocysts in human stool specimens: evidence for low sensitivity of current diagnostic methods. J Clin Microbiol 1991;29:1323-7. |
|
| 484.
| | Garcia LS, Shimizu RY. Evaluation of nine immunoassay kits (enzyme immunoassay and direct fluorescence) for detection of Giardia lamblia and Cryptosporidium parvum in human fecal specimens. J Clin Microbiol 1997;35:1526-9. |
|
| 485.
| | Garcia LS, Shimizu RY, Novak S, et al. Commercial assay for detection of Giardia lamblia and Cryptosporidium parvum antigens in human fecal specimens by rapid solid-phase qualitative immunochromatography. J Clin Microbiol 2003;41:209-12. |
|
| 486.
| | McLauchlin J, Amar CF, Pedraza-Díaz S, et al. Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatr Infect Dis J 2003;22: 329-35. |
|
| 487.
| | Menotti J, Cassinat B, Porcher R, et al. Development of a real-time polymerase-chain-reaction assay for quantitative detection of Enterocytozoon bieneusi DNA in stool specimens from immunocompromised patients with intestinal microsporidiosis. J Infect Dis 2003;187:1469-74. |
|
| 488.
| | Holmberg SD, Moorman AC, Von Bargen JC, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA 1998;279:384-6. |
|
| 489.
| | Fichtenbaum CJ, Zackin R, Feinberg J, et al. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS 2000;14:2889-93. |
|
| 490.
| | Miao YM, Awad-El-Kariem FM, Franzen C, et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:124-9. |
|
| 491.
| | . Abubakar I, Abubakar I, Aliyu SH, et al. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev 2007;Jan 24:CD004932. |
|
| 492.
| | Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, doubleblind, placebo-controlled study of Nitazoxanide. J Infect Dis 2001; 184:103-6. |
|
| 493.
| | Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial Lancet 2000;360:1375-80. |
|
| 494.
| | Rossignol JF, Hidalgo H, Feregrino M, et al. A double-“blind” placebocontrolled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998;92:663-6. |
|
| 495.
| | White AC, Chappell CL, Hayat CS, et al. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J Infect Dis 1994;170:419-24. |
|
| 496.
| | Hewitt RG, Yiannoutsos CT, Higgs ES, et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis 2000;31:1084-92. |
|
| 497.
| | Hicks P, Zwiener RJ, Squires J, et al. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. J Pediatr 1996;129:297-300. |
|
| 498.
| | Weber R, Sauer B, Lthy R, et al. Intestinal coinfection with Enterocytozoon bieneusi and Cryptosporidium in a human immunodeficiency virusinfected child with chronic diarrhea. Clin Infect Dis 1993;17:480-3. |
|
| 499.
| | Molina JM, Chastang C, Goguel J, et al. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1998;177:1373-7. |
|
| 500.
| | Didier PJ, Phillips JN, Kuebler DJ, et al. Antimicrosporidial activities of fumagillin, TNP-470, ovalicin, and ovalicin derivatives in vitro and in vivo. Antimicrob Agents Chemother 2006;50:2146-55. |
|
| 501.
| | Bicart-See A, Massip P, Linas MD, et al. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. Antimicrob Agents Chemother 2000;44:167-8. |
|
| 502.
| | Diesenhouse MC, Wilson LA, Corrent GF, et al. Treatment of microsporidial keratoconjunctivitis with topical fumagillin. Am J Ophthalmol 1993;115:293-8. |
|
| 503.
| | Didier ES. Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro. Antimicrob Agents Chemother 1997;41:1541-6. |
|
| 504.
| | Thwing J, Skarbinski J, Newman RD, et al. Malaria surveillance- United States, 2005. In: Surveillance Summaries, June 8, 2007. |
|
| 505.
| | Rivera-Matos IR, Atkins JT, Doerr CA, et al. Pediatric malaria in Houston, Texas. Am J Trop Med Hyg 1997;57:560-3. |
|
| 506.
| | Emanuel B, Aronson N, Shulman S. Malaria in children in Chicago. Pediatrics 1993;92:83-5. |
|
| 507.
| | Miller KK, Banerji A. Epidemiology of malaria presenting at British Columbia's Children's Hospital, 1984-2001: lessons for prevention. Can J Public Health 2004;95:245-8. |
|
| 508.
| | Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356:1051-6. |
|
| 509.
| | Patnaik P, Jere CS, Miller WC, et al. Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis 2005;192:984-91. |
|
| 510.
| | Greenberg AE, Nsa W, Ryder RW, et al. Plasmodium falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study of 587 children. N Engl J Med 1991;325:105-9. |
|
| 511.
| | Taha TE, Canner JK, Dallabetta GA, et al. Childhood malaria parasitaemia and human immunodeficiency virus infection in Malawi. Trans R Soc Trop Med Hyg 1994;88:164-5. |
|
| 512.
| | Kalyesubula I, Musoke-Mudido P, Marum L, et al. Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children. Pediatr Infect Dis J 1997;16:876-81. |
|
| 513.
| | Villamor E, Fataki MR, Mbise RL, et al. Malaria parasitaemia in relation to HIV status and vitamin A supplementation among preschool children. Trop Med Int Health 2003;8:1051-61. |
|
| 514.
| | Rogerson SR, Gladstone M, Callaghan M, et al. HIV infection among paediatric in-patients in Blantyre, Malawi. Trans R Soc Trop Med Hyg 2004;98:544-52. |
|
| 515.
| | Grimwade K, French N, Mbatha DD, et al. Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatr Infect Dis J 2003;22:1057-63. |
|
| 516.
| | Otieno RO, Ouma C, Ong'echa JM, et al. Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria. AIDS 2006;20:275-80. |
|
| 517.
| | Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004;364:1428-34. |
|
| 518.
| | Skarbinski J, James EM, Causer LM, et al. Malaria surveillance-United States, 2004. In: Surveillance Summaries, May 26, 2006. MMWR 2006;55(No. SS-4):23-37. |
|
| 519.
| | Shingadia D, Shulman ST. Recognition and management of imported malaria in children Seminars in Pediatr Infect Dis 2000;11:172-7. |
|
| 520.
| | Stauffer WM, Maroushek S, Kamat D. Medical screening of immigrant children. Clin Pediatr (Phila) 2003;42:763-73. |
|
| 521.
| | Maroushek SR, Aguilar EF, Stauffer W, et al. Malaria among refugee children at arrival in the United States. Pediatr Infect Dis J 2005;24:450-2. |
|
| 522.
| | Ndao M, Bandyayera E, Kokoskin E, et al. Comparison of blood smear, antigen detection, and nested-PCR methods for screening refugees from regions where malaria is endemic after a malaria outbreak in Quebec, Canada. J Clin Microbiol 2004;42:2694-700. |
|
| 523.
| | Stauffer WM, Newberry AM, Cartwright CP, et al. Evaluation of malaria screening in newly arrived refugees to the United States by microscopy and rapid antigen capture enzyme assay. Pediatr Infect Dis J 2006;25:948-50. |
|
| 524.
| | Bacaner N, Stauffer B, Boulware DR, et al. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 2004;291:2856-64. |
|
| 525.
| | Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1499-539. |
|
| 526.
| | Stauffer WM, Kamat D, Magill AJ. Traveling with infants and children. Part IV: insect avoidance and malaria prevention. J Travel Med 2003;10:225-40. |
|
| 527.
| | Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim- sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 2007;21:2059-66. 114 MMWR September 4, 2009 |
|
| 528.
| | Kamya MR, Gasasira AF, Yeka A, et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis 2006;193:9-15. |
|
| 529.
| | Byakika-Kibwika P, Ddumba E, Kamya M. Effect of HIV-1 infection on malaria treatment outcome in Ugandan patients. Afr Health Sci 2007;7:86-92. |
|
| 530.
| | Stauffer WM, Fischer PR. Diagnosis and treatment of malaria in children. Clin Infect Dis 2003;37:1340-8. |
|
| 531.
| | CDC. New medication for severe malaria available under an investigational new drug protocol. MMWR 2007;56:769-770. |
|
| 532.
| | Newton PN, McGready R, Fernandez F, et al. Manslaughter by fake artesunate in Asia- will Africa be next? PLoS Med 2006;3:e197. |
|
| 533.
| | Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 1994;330:1858-63. |
|
| 534.
| | Jara M, Hsu HW, Eaton RB, et al. Epidemiology of congenital toxoplasmosis identified by population-based newborn screening in Massachusetts. Pediatr Infect Dis J 2001;20:1132-5. |
|
| 535.
| | Smith KL, Wilson M, Hightower AW, et al. Prevalence of Toxoplasma gondii antibodies in US military recruits in 1989: comparison with data published in 1965. Clin Infect Dis 1996;23:1182-3. |
|
| 536.
| | Jones JL, Kruszon-Moran D, Wilson M, et al. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 2001;154:357-65. |
|
| 537.
| | Dunn D, Wallon M, Peyron F, et al. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling Lancet 1999;353:1829-33. |
|
| 538.
| | Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis 2002;185(Suppl 1):S73-82. |
|
| 539.
| | Falusi O, French AL, Seaberg EC, et al. Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis 2002;35:1414-7. |
|
| 540.
| | Minkoff H, Remington JS, Holman S, et al. Vertical transmission of Toxoplasma by human immunodeficiency virus-infected women. Am J Obstet Gynecol 1997;176:555-9. |
|
| 541.
| | Dunn D, Newell ML, Gilbert R. Low risk of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. Pediatr Infect Dis J 1997;16:84. |
|
| 542.
| | Dunn DT, Newell ML, Gilbert R, et al. Low incidence of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. European Collaborative Study and Research Network on Congenital Toxoplasmosis. Eur J Obstet Gynecol Reprod Biol 1996;68:93-6. |
|
| 543.
| | Mitchell CD, Erlich SS, Mastrucci MT, et al. Congenital toxoplasmosis occurring in infants perinatally infected with human immunodeficiency virus 1. Pediatr Infect Dis J 1990;9:512-8. |
|
| 544.
| | D'Offizi G, Topino S, Anzidei G, et al. Primary Toxoplasma gondii infection in a pregnant human immunodeficiency virus-infected woman. Pediatr Infect Dis J 2002;21:981-2. |
|
| 545.
| | Vogel N, Kirisits M, Michael E, et al. Congenital toxoplasmosis transmitted from an immunologically competent mother infected before conception. Clin Infect Dis 1996;23:1055-60. |
|
| 546.
| | CDC. HIV/AIDS surveillance report. 1996:8(2):1-18. |
|
| 547.
| | Sobanjo A, Ferguson DJ, Gross U. Primary acquired toxoplasmosis in a five-year-old child with perinatal human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 1999;18:476-8. |
|
| 548.
| | Wahn V, Kramer HH, Voit T, et al. Horizontal transmission of HIV infection between two siblings. Lancet 1986;2:694. |
|
| 549.
| | King SM, Matlow A, Al-Hajjar S, et al. Toxoplasmic encephalitis in a child with HIV infection-United States. Pediatr AIDS and HIV Infect. Fetus to Adolesc 1992: 3:242-4. |
|
| 550.
| | McAuley J, Boyer KM, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994;18:38-72. |
|
| 551.
| | Medlock MD, Tilleli JT, Pearl GS. Congenital cardiac toxoplasmosis in a newborn with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1990;9:129-32. |
|
| 552.
| | Pinon JM, Dumon H, Chemla C, et al. Strategy for diagnosis of congenital toxoplasmosis: evaluation of methods comparing mothers and newborns and standard methods for postnatal detection of immunoglobulin G, M, and A antibodies. J Clin Microbiol 2001;39:2267-71. |
|
| 553.
| | Wilson M, Jones JL, McAuley JB. Toxoplasma. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Manual of clinical microbiology, 9th ed. St. Louis, MO: ASM Press; 2007:2070-81. |
|
| 554.
| | Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004;363:1965-76. |
|
| 555.
| | Wong SY, Hajdu MP, Ramirez R, et al. Role of specific immunoglobulin E in diagnosis of acute Toxoplasma infection and toxoplasmosis. J Clin Microbiol 1993;31:2952-9. |
|
| 556.
| | Portegies P, Solod L, Cinque P, et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol 2004;11:297-304. |
|
| 557.
| | Offiah CE, Turnbull IW. The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients. Clin Radiol 2006;61:393-401. |
|
| 558.
| | U.S. Department of Agriculture. FoodSafety.gov: gateway to government food safety information. Washington, DC: US Departent of Agriculture, 2002. Available at http://www.foodsafety.gov. |
|
| 559.
| | Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim- sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995; 122:755-61. |
|
| 560.
| | Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995;20:531-41. |
|
| 561.
| | Kirk O, Lundgren JD, Pedersen C, et al. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 1999;13:1647-51. |
|
| 562.
| | Furrer H, Opravil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of Toxoplasma,/i> encephalitis. Swiss HIV Cohort Study. Lancet 2000;355:2217-8. |
|
| 563.
| | Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000;181:1635-42. |
|
| 564.
| | Miro JM, Lopez JC, Podzamczer D, et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis 2006;43:79-89. |
|
| 565.
| | SYROCOT (Systematic Review on Congenital Toxoplasmosis) Study Group, Thiébaut R, Leproust S, et al. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 2007;369:115-22. |
|
| 566.
| | McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based Congenital Toxoplasmosis Study. Clin Infect Dis 2006;42:1383-94. |
|
| 567.
| | Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005;112:1876-82. |
|
| 568.
| | Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr Opin Infect Dis 2007;20:482-8. |
|
| 569.
| | Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996;22:268-75. |
|
| 570.
| | Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992;116:33-43. |
|
| 571.
| | Duval X, Pajot O, Le Moing V, et al. Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy. AIDS 2004;18:1342-4. |
|
| 572.
| | Soriano V, Dona C, Rodriguez-Rosado R, et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIVinfected patients receiving highly active antiretroviral therapy. AIDS 2000;14:383-6. |
|
| 573.
| | Bertschy S, Opravil M, Cavassini M, et al. Discontinuation of maintenance therapy against Toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. Clin Microbiol Infect 2006;12:666-71. |
|
| 574.
| | Stagno S, Reynolds DW, Pass RF, et al. Breast milk and the risk of cytomegalovirus infection. N Engl J Med 1980;302:1073-6. |
|
| 575.
| | Pass RF, Hutto C, Reynolds DW, et al. Increased frequency of cytomegalovirus infection in children in group day care. Pediatrics 1984;74:121-6. |
|
| 576.
| | Adler SP. Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med 1989;321:1290-6. |
|
| 577.
| | Pass RF. Epidemiology and transmission of cytomegalovirus infection. J Infect Dis 1985;152:243-8. |
|
| 578.
| | Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 1986;256:1904-8. |
|
| 579.
| | Yow MD, Williamson DW, Leeds LJ, et al. Epidemiologic characteristics of cytomegalovirus infection in mothers and their infants. Am J Obstet Gynecol 1998;158:1189-95. |
|
| 580.
| | Mussi-Pinhata MM, Yamamoto AY, Figueiredo LT, et al. Congenital and perinatal cytomegalovirus infection in infants born to mothers infected with human immunodeficiency virus. J Pediatr 1998;132:285-90. |
|
| 581.
| | Quinn TC, Piot P, McCormick JB, et al. Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. JAMA 1987;257:2617-21. |
|
| 582.
| | Prober CG, Enright AM. Congenital cytomegalovirus (CMV) infections: hats off to Alabama J Pediatr 2003;143:4-6. |
|
| 583.
| | Revello MG, Zavattoni M, Furione M, et al. Diagnosis and outcome of preconceptional and periconceptional primary human cytomegalovirus infections. J Infect Dis 2002;186:553-7. |
|
| 584.
| | Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003;289:1008-11. |
|
| 585.
| | Azam AZ, Vial Y, Fawer CL, et al. Prenatal diagnosis of congenital cytomegalovirus infection. Obstet Gynecol 2001;97:443-8. |
|
| 586.
| | Boppana SB, Fowler KB, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 1999;104:55-60. |
|
| 587.
| | Boppana SB, Rivera LB, Fowler KB, et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001;344:1366-71. |
|
| 588.
| | Mostad SB, Kreiss JK, Ryncarz A, et al. Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type 1. Am J Obstet Gynecol 2000;183:948-55. |
|
| 589.
| | Kitchen BJ, Engler HD, Gill VJ, et al. Cytomegalovirus infection in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1997;16:358-63. |
|
| 590.
| | Jabs DA, Van Natta ML, Holbrook JT, et al. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology 2007;114:780-6. |
|
| 591.
| | Chandwani S, Kaul A, Bebenroth D, et al. Cytomegalovirus infection in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 1996;15:310-4. |
|
| 592.
| | Boppana SB, Pass RF, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 1992;11:93-9. |
|
| 593.
| | Fowler KB, Boppana SB. Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol 2006;35:226-31. |
|
| 594.
| | Doyle M, Atkins JT, Rivera-Matos IR. Congenital cytomegalovirus infection in infants infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1996;15:1102-6. |
|
| 595.
| | Zaknun D, Zangerle R, Kapelari K, et al. Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review. Pediatr Infect Dis J 1997;16:807-11. |
|
| 596.
| | Mueller BU, MacKay K, Cheshire LB, et al. Cytomegalovirus ureteritis as a cause of renal failure in a child infected with the human immunodeficiency virus. Clin Infect Dis 1995;20:1040-3. |
|
| 597.
| | Olivero MT, Nelson RP Jr, Andrews T, et al. Cytomegalovirus sinus disease in a human immunodeficiency virus-infected child. Pediatr Infect Dis J 1995;14:629-31. |
|
| 598.
| | Marriage SC, Booy R, Hermione Lyall EG, et al. Cytomegalovirus myelitis in a child infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1996;15:549-51. |
|
| 599.
| | Kalayjian RC, Cohen ML BR, Flanigan TP. Cytomegalovirus ventriculoencephalitis in AIDS. A syndrome with distinct clinical and pathologic features. Medicine (Baltimore) 1993;72:67-77. |
|
| 600.
| | Nigro G, Krzysztofiak A, Gattinara GC, et al. Rapid progression of HIV disease in children with cytomegalovirus DNAemia. AIDS 1996;10:1127-33. |
|
| 601.
| | Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997;175:1080-6. 116 MMWR September 4, 2009 |
|
| 602.
| | Kimberlin DW, Lin CY, Sánchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial J Pediatr 2003;143:16-25. |
|
| 603.
| | Oliver S, Cloug G, Sánchez P, et al. Effect of ganciclovir therapy on neurodevelopmental outcomes in symptomatic congenital cytomegalovirus infections involving the central nervous system: a randomized, controlled study [abstract 752908]. Society for Pediatric Research, San Francisco, California, April 29, 2006. The Woodlands, Texas: Society for Pediatric Research; 2006: Available at http://www. abstracts2view.com/pas. Citation: E-PAS2006:59:2540.2. |
|
| 604.
| | Studies of Ocular Complications of AIDS Research, Group in collaboration with the AIDS Clinical Trials Group. Foscarnet- Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology 1994;101:1250-61. |
|
| 605.
| | Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med 1997;337:83-90. |
|
| 606.
| | Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002;346:1119-26. |
|
| 607.
| | Kempen JH, Jabs DA, Wilson LA, et al. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol 2003;121:466-76. |
|
| 608.
| | Studies of Ocular Complications of AIDS Research Group, The AIDS Clinical Trials Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Am J Ophthalmol 2001;131: 457-67. |
|
| 609.
| | Acosta EP, Brundage RC, King JR, et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007;81:867-72. |
|
| 610.
| | Walton RC, Whitcup SM, Mueller BU, et al. Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. Ophthalmology 1995;102:1865-70. |
|
| 611.
| | Butler KM, De Smet MD, Husson RN, et al. Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. J Pediatr 1992;120:483-6. |
|
| 612.
| | Fletcher C, Sawchuk R, Chinnock B, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986;40:281-6. |
|
| 613.
| | Nguyen QD, Kempen JH, Bolton SG, et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000;129:634-9. |
|
| 614.
| | Kosobucki BR, Goldberg DE, Bessho K, et al. Valganciclovir therapy for immune recovery uveitis complicated by macular edema. Am J Ophthalmol 2004;137:636-8. |
|
| 615.
| | Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999;340:1063-70. |
|
| 616.
| | Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med 1995;333:615-20. |
|
| 617.
| | Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med 1997;126:264-74. |
|
| 618.
| | Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991;115:665-73. |
|
| 619.
| | Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis 1993;168:557-63. |
|
| 620.
| | The Studies of the Ocular Complications of AIDS Research Group, Group icwtACT. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The cytomegalovirus retreatment trial. Arch Ophthalmol 1996;114:23-33. |
|
| 621.
| | Diaz-Llopis M, España E, Muñoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol 1994;78:120-4. |
|
| 622.
| | de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen- a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm 1999;7:189-98. |
|
| 623.
| | Kirsch LS, Arevalo JF, Chavez de la Paz E, et al. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995;102: 533-42; discussion 542-3. |
|
| 624.
| | Young S, Morlet N, Besen G, et al. High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology 1998;105:1404-10. |
|
| 625.
| | Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998;177: 1080-3. |
|
| 626.
| | Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 1998;105:1259-64. |
|
| 627.
| | Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177: 1182-7. |
|
| 628.
| | Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999;282:1633-7. |
|
| 629.
| | Jabs DA, Bolton SG, Dunn JP, et al. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998;126:817-22. |
|
| 630.
| | Jouan M, Saves M, Tubiana R, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2001;15:23-31. |
|
| 631.
| | Torriani FJ, Freeman WR, Macdonald JC, et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 2000;14:173-80. Vol. 58 / RR-11 Recommendations and Reports 117 |
|
| 632.
| | Lilleri D, Piccinini G, Genini E, et al. Monitoring of human cytomegalovirus (HCMV)-specific CD4+ T cell frequency by cytokine flow cytometry as a possible indicator for discontinuation of HCMV secondary prophylaxis in HAART-treated AIDS patients. J Clin Virol 2004;29:297-307. |
|
| 633.
| | Tamarit A, Alberola J, Mira JV, et al. Assessment of human cytomegalovirus specific T cell immunity in human immunodeficiency virus infected patients in different disease stages following HAART and in long-term non-progressors. J Med Virol 2004;74:382-9. |
|
| 634.
| | Weingberg A, Wiznia AA, Lafleur BJ, et al. Cytomegalovirus-specific cell-mediated immunity in HIV-infected children on HAART. AIDS Res Hum Retroviruses 2006;22:283-8. |
|
| 635.
| | Saitoh A, Viani RM, Schrier RD, et al. Treatment of infants coinfected with HIV-1 and cytomegalovirus with combination antiretrovirals and ganciclovir. J Allergy Clin Immunol 2004;114:983-5. |
|
| 636.
| | Spector SA, Wong R, Hsia K, et al. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998;101:497-502. |
|
| 637.
| | Salmon-Ceron D, Mazeron MC, Chaput S, et al. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS 2000;14:1041-9. |
|
| 638.
| | Chu CM, Karayiannis P, Fowler MJ, et al. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985;5:431-4. |
|
| 639.
| | Chang MH, Sung JL, Lee CY, et al. Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children. J Pediatr 1989;115:385-90. |
|
| 640.
| | Elisofon SA, Jonas MM. Hepatitis B and C in children: current treatment and future strategies. Clin Liver Dis 2006;10:133-48. |
|
| 641.
| | Rogers AS, Lindsey JC, Futterman DC, et al. Serologic examination of hepatitis B infection and immunization in HIV-positive youth and associated risks. The Pediatric AIDS Clinical Trials Group Protocol 220 Team. AIDS Patient Care STDS 2000;14:651-7. |
|
| 642.
| | Wang EE, King S, Goldberg E, et al. Hepatitis B and human immunodeficiency virus infection in street youths in Toronto, Canada. Pediatr Infect Dis J 1991;10:130-3. |
|
| 643.
| | Mieli-Vergani G, Vergani D. Treatment of hepatitis B virus in children: why, whom, how? Indian J Gastroenterol 2006;25:121-4. |
|
| 644.
| | Wasley A, Kruszon-Moran D, Kuhnert W, et al. Hepatitis B prevalence in the U.S. in the era of vaccination [abstract 723]. In: Abstracts of the Infectious Diseases Society of America 45th annual meeting; October 4-7, 2007; San Diego, CA. Arlington VA: Infectious Diseases Society of America; 2007:171. |
|
| 645.
| | Toussi SS, Abadi J, Rosenberg M, et al. Prevalence of hepatitis B and C virus infections in children infected with HIV. Clin Infect Dis 2007;45:795-8. |
|
| 646.
| | Tovo PA, Lazier L, Versace A. Hepatitis B virus and hepatitis C virus infections in children. Curr Opin Infect Dis 2005;18:261-6. |
|
| 647.
| | Bortolotti F, Calzia R, Cadrobbi P, et al. Liver cirrhosis associated with chronic hepatitis B virus infection in childhood. J Pediatr 1986;108:224-7. |
|
| 648.
| | Chen CH, Chen YY, Chen GH, et al. Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. J Hepatol 2004;40:653-9. |
|
| 649.
| | Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006;43:556-62. |
|
| 650.
| | Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. |
|
| 651.
| | Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007;356:1445-54. |
|
| 652.
| | Chang MH, Hsu HY, Hsu HC, et al. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 1995;22:1387-92. |
|
| 653.
| | Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004;116:829-34. |
|
| 654.
| | Rutstein RM, Rudy B, Codispoti C, et al. Response to hepatitis B immunization by infants exposed to HIV. AIDS 1994;8:1281-4. |
|
| 655.
| | Siriaksorn S, Puthanakit T, Sirisanthana T, et al. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 2006;24:3095-9. |
|
| 656.
| | Shneider BL, González-Peralta R, Roberts EA. Controversies in the management of pediatric liver disease: hepatitis B, C and NAFLD. Summary of a single topic conference. Hepatology 2006;44:1344-54. |
|
| 657.
| | Jain MK, Comanor L, White C, et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat 2007;14:176-82. |
|
| 658.
| | Jonas MM. Treatment of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr 2006;43(Suppl 1):S56-60. |
|
| 659.
| | Heller S, Valencia-Mayoral P. Treatment of viral hepatitis in children. Arch Med Res 2007;38:702-10. |
|
| 660.
| | Sokucu S, Gokçe S, Suoglu OD, et al. Comparison of interferon monotherapy with interferon-lamivudine combination treatment in children with chronic hepatitis B. Indian J Gastroenterol 2006;25:136-9. |
|
| 661.
| | Kansu A, Doganci T, Akman SA, et al. Comparison of two different regimens of combined interferon-alpha2a and lamivudine therapy in children with chronic hepatitis B infection. Antivir Ther 2006;11:255-61. |
|
| 662.
| | Yilmaz A, Akcam M, Gelen T, et al. Lamivudine and high-dose interferon alpha 2a combination treatment in nave HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean centers experience. Eur J Pediatr 2007;166:195-9. |
|
| 662.
| | Yilmaz A, Akcam M, Gelen T, et al. Lamivudine and high-dose interferon alpha 2a combination treatment in naïve HBeAg-positive immunoactive chronic hepatitis B in children: an East Mediterranean center's experience. Eur J Pediatr 2007;166:195-9. |
|
| 663.
| | DAntiga L, Aw M, Atkins M, et al. Combined lamivudine/interferonalpha treatment in immunotolerant children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006;148:228-33. |
|
| 663.
| | D'Antiga L, Aw M, Atkins M, et al. Combined lamivudine/interferonalpha treatment in «immunotolerant» children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006;148:228-33. |
|
| 664.
| | Saltik-Temizel IN, Kocak N, Demir H. Lamivudine and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection. J Clin Gastroenterol 2005;39:68-70. |
|
| 664.
| | Saltik-Temizel IN, Koçak N, Demir H. Lamivudine and high-dose interferon-alpha combination therapy for naive children with chronic hepatitis B infection. J Clin Gastroenterol 2005;39:68-70. |
|
| 665.
| | Ozgenc F, Dikici B, Targan S, et al. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection. Antivir Ther 2004;9:23-6. |
|
| 666.
| | Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAgnegative chronic hepatitis B. N Engl J Med 2004;351:1206-17. |
|
| 667.
| | Dikici B, Bosnak M, Kara IH, et al. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. Pediatr Infect Dis J 2001;20:988-92. |
|
| 668.
| | Dikici G, Ozgenc F, Kalayci AG, et al. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study. J Gastroenterol Hepatol 2004;19:127-33. 118 MMWR September 4, 2009 |
|
| 669.
| | Kuloglu Z, Krsacloglu CT, Kansu A, et al. Liver histology of children with chronic hepatitis treated with interferon-a alone or in combination with lamivudine. J Pediatr Gastroenterol Nutr 2007;45:564-8. |
|
| 670.
| | Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996;23:131-7. |
|
| 671.
| | Gurakan F, Koçak N, Ozen H, et al. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatr Infect Dis J 2000;19:52-6. |
|
| 672.
| | Yuce A, Koçak N, Ozen H, et al. Prolonged interferon alpha treatment in children with chronic hepatitis B. Ann Trop Paediatr 2001;21:77-80. |
|
| 673.
| | Choe BH, Lee JH, Jang YC, et al. Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better. J Pediatr Gastroenterol Nutr 2007;44:92-8. |
|
| 674.
| | Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95. |
|
| 675.
| | Schwarz KB, Mohan P, Narkewicz MR, et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2006;43:499-505. |
|
| 676.
| | Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;415. |
|
| 677.
| | Baker RD, Dee D, Baker SS. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. J Clin Gastroenterol 2007;41:111-4. |
|
| 678.
| | Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13. |
|
| 679.
| | Sokal EM, Kelly DA, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-32. |
|
| 680.
| | Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006;44:62-7. |
|
| 681.
| | Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005;25 (Suppl 1): 9-19. |
|
| 682.
| | Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-6. |
|
| 683.
| | Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20. |
|
| 684.
| | McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir- effects on HIV-1 replication and resistance. N Engl J Med 2007; 356:2614-21. |
|
| 685.
| | Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-95. |
|
| 686.
| | Gonzalez-Peralta R, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005;42:1010-8. |
|
| 687.
| | Kuloglu Z, Kansu A, Berberoglu M, et al. The incidence and evolution of thyroid dysfunction during interferon-alpha therapy in children with chronic hepatitis B infection. J Pediatr Endocrinol Metab 2007;20:237-45. |
|
| 688.
| | Comanor L, Minor J, Conjeevaram HS, et al. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. J Viral Hepat 2001;8:139-47. |
|
| 689.
| | Jara P, Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999;29:163-70. |
|
| 690.
| | Vajro P, Migliaro F, Fontanella A, et al. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg 1998;61:219-23. |
|
| 691.
| | Ozen H, Koçak N, Yüce A, et al. Retreatment with higher dose interferon alpha in children with chronic hepatitis B infection. Pediatr Infect Dis J 1999;18:694-7. |
|
| 692.
| | Kocak N, Saltik IN, Ozen H, et al. Lamivudine treatment for children with interferon refractory chronic hepatitis B. Hepatology 2000;31:545. |
|
| 693.
| | Sokal EM, Roberts EA, Mieli-Vergani G, et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000;44:590-7. |
|
| 694.
| | Hartman C, Berkowitz D, Eshach-Adiv O, et al. Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon. J Pediatr Gastroenterol Nutr 2006;43:494-8. |
|
| 695.
| | Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62. |
|
| 696.
| | El-Kamary SS, Serwint JR, Joffe A, et al. Prevalence of hepatitis C virus infection in urban children. J Pediatr 2003;143:54-9. |
|
| 697.
| | Schuval S, Van Dyke RB, Lindsey JC, et al. Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med 2004;158:1007-13. |
|
| 698.
| | England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis 2006;6:83-90. |
|
| 699.
| | Tajiri H, Miyoshi Y, Funada S, et al. Prospective study of motherto- infant transmission of hepatitis C virus. Pediatr Infect Dis J 2001;20:10-4. |
|
| 700.
| | Jara P, Resti M, Hierro L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003;36:275-80. |
|
| 701.
| | Murray KF, Richardson LP, Morishima C, et al. Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics 2003;111:153-7. |
|
| 702.
| | Cagle HH, Jacob J, Homan CE, et al. Results of a general hepatitis C lookback program for persons who received blood transfusions in a neonatal intensive care unit between January 1975 and July 1992. Arch Pediatr Adolesc Med 2007;161:125-30. |
|
| 703.
| | Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med 2007;131:702-7. |
|
| 704.
| | Tovo PA, Palomba E, Ferraris G, et al. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clin Infect Dis 1997;25:1121-4. |
|
| 705.
| | Zanetti AR, Tanzi E, Romanò L, et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998;41:208-12. |
|
| 706.
| | Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000;356:904-7. Vol. 58 / RR-11 Recommendations and Reports 119 |
|
| 707.
| | European Paediatric Hepaptitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. Bjog 2001;108:371-7. |
|
| 708.
| | Granovsky MO, Minkoff HL, Tess BH, et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 1998;102(2 Pt 1): 355-9. |
|
| 709.
| | Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998;317:437-41. |
|
| 710.
| | Thomas SL, Newell ML, Peckham CS, et al. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998;27:108-17. |
|
| 711.
| | Mazza C, Ravaggi A, Rodella A, et al. Prospective study of mother-toinfant transmission of hepatitis C virus (HCV) infection. Study Group for Vertical Transmission. J Med Virol 1998;54:12-9. |
|
| 712.
| | Okamoto M, Nagata I, Murakami J, et al. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis 2000;182:1511-4. |
|
| 713.
| | Dal Molin G, D'Agaro P, Ansaldi F, et al. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. J Med Virol 2002;67:137-42. |
|
| 714.
| | Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005;192:1880-9. |
|
| 715.
| | Ruiz-Extremera A, Salmerön J, Torres C, et al. Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission. Pediatr Infect Dis J 2000;19:511-6. |
|
| 716.
| | Polis CB, Shah SN, Johnson KE, et al. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a metaanalysis. Clin Infect Dis 2007;44:1123-31. |
|
| 717.
| | Mok J, Pembrey L, Tovo PA, et al. When does mother to child transmission of hepatitis C virus occur? Arch Dis Child Fetal Neonatal Ed 2005;90:F156-60. |
|
| 718.
| | Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000;31:751-5. |
|
| 719.
| | Papaevangelou V, Pollack H, Rochford G, et al. Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women. J Infect Dis 1998;178:1047-52. |
|
| 720.
| | Marine-Barjoan E, Berrébi A, Giordanengo V, et al. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? AIDS 2007;21: 1811-5. |
|
| 721.
| | European Paediatric Hepatitis C Virus Network. A significant sex-but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005;192:1872-9. |
|
| 722.
| | Lin HH, Kao JH, Hsu HY, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr 1995;126: 589-91. |
|
| 723.
| | Pappalardo B. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol 2003;32:727-34. |
|
| 724.
| | Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998;177:1480-8. |
|
| 725.
| | Paccagini S, Principi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995;14:195-9. |
|
| 726.
| | Hershow RC, Riester KA, Lew J, et al. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study. J Infect Dis 1997;176:414-20. |
|
| 727.
| | Nigro G, D'Orio F, Catania S, et al. Mother to infant transmission of coinfection by human immunodeficiency virus and hepatitis C virus: prevalence and clinical manifestations. Arch Virol 1997;142:453-7. |
|
| 728.
| | Giovannini M, Tagger A, Ribero ML, et al. Maternal-infant transmission of hepatitis C virus and HIV infections: a possible interaction. Lancet 1990;335:1166. |
|
| 729.
| | Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 2007;297:724-32. |
|
| 730.
| | El Sherbini A, Hassan W, Abdel-Hamid M, et al. Natural history of hepatitis C virus among apparently normal schoolchildren: follow-up after 7 years. J Trop Pediatr 2003;49:384-5. |
|
| 731.
| | Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol 2004;19:1357-62. |
|
| 732.
| | England K, Pembrey L, Tovo PA, et al. Growth in the first 5 years of life is unaffected in children with perinatally acquired hepatitis C infection. J Pediatr 2005;147:227-32. |
|
| 733.
| | Resti M, Jara P, Hierro L, et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 2003;70:373-7. |
|
| 734.
| | European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005;41:45-51. |
|
| 735.
| | Bortolotti F, Resti M, Marcellini M, et al. Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome. Gut 2005;54:852-7. |
|
| 736.
| | Guido M, Rugge M, Jara P, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998;115: 1525-9. |
|
| 737.
| | Aach RD, Yomtovian RA, Hack M. Neonatal and pediatric posttransfusion hepatitis C: a look back and a look forward. Pediatrics 2000;105(4 Pt 1):836-42. |
|
| 738.
| | Mohan P, Colvin C, Glymph C, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 2007;150:168-74, 174.e1. |
|
| 739.
| | Davison SM, Mieli-Vergani G, Sira J, et al. Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Child 2006; 91:781-5. |
|
| 740.
| | Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection. J Infect Dis 2000;181:419-24. |
|
| 741.
| | Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-9. |
|
| 742.
| | Merchante N, Girön-González JA, González-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006;20:49-57. 120 MMWR September 4, 2009 |
|
| 743.
| | Shivraj SO, Chattopadhya D, Grover G, et al. Role of HCV coinfection towards disease progression and survival in HIV-1 infected children: a follow-up study of 10 years. J Trop Pediatr 2006;52:206-11. |
|
| 744.
| | Dunn DT, Gibb DM, Healy M, et al. Timing and interpretation of tests for diagnosing perinatally acquired hepatitis C virus infection. Pediatr Infect Dis J 2001;20:715-6. |
|
| 745.
| | Polywka S, Pembrey L, Tovo PA, et al. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 2006;78:305-10. |
|
| 746.
| | Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for mternal health and interventions to reduce perinatal HIV-1 transmission in the United States. July 8, 2008:1-98. Available at http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. |
|
| 747.
| | CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR-19). |
|
| 748.
| | Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71. |
|
| 749.
| | Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-89. |
|
| 750.
| | Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82. |
|
| 751.
| | Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9. |
|
| 752.
| | Narkewicz MR, Cabrera R, Gonzalez-Peralta RP. The ”C” of viral hepatitis in children. Semin Liver Dis 2007;27:295-311. |
|
| 753.
| | Christensson B, Wiebe T, Akesson A, et al. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000;30:585-6. |
|
| 754.
| | Lackner H, Moser A, Deutsch J, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000;106:E53. |
|
| 755.
| | Kowala-Piaskowska A, Sluzewski W, Figlerowicz M, et al. Early virological response in children with chronic hepatitis C treated with pegylated interferon and ribavirin. Infection 2007;35:175-9. |
|
| 756.
| | Wirth S, Lang T, Gehring S, et al. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002;36:1280-4. |
|
| 757.
| | Caserta MT, McDermott MP, Dewhurst S, et al. Human herpesvirus 6 (HHV6) DNA persistence and reactivation in healthy children. J Pediatr 2004;145:478-84. |
|
| 758.
| | Kositanont U, Wasi C, Wanprapar N, et al. Primary infection of human herpesvirus 6 in children with vertical infection of human immunodeficiency virus type 1. J Infect Dis 1999;180:50-5. |
|
| 759.
| | Zerr D, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med 2005;352:768-76. |
|
| 760.
| | Hall CB, Caserta MT, Schnabel KC, et al. Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7). J Pediatr 2004;145:472-7. |
|
| 761.
| | Pruksananonda P, Hall CB, Insel RA, et al. Primary human herpesvirus 6 infection in young children. N Engl J Med 1992;326:1445-50. |
|
| 762.
| | Okuno T, Oishi H, Hayashi K, et al. Human herpesviruses 6 and 7 in cervixes of pregnant women. J Clin Microbiol 1995;33:1968-70. |
|
| 763.
| | Bailllargeon J, Piper J, Leach CT. Epidemiology of human herpesvirus 6 (HHV-6) infection in pregnant and nonpregnant women. J Clin Virol 2000;16:149-57. |
|
| 764.
| | Adams O, Krempe C, Kgler G, et al. Congenital infections with human herpesvirus 6. J Infect Dis 1998;178:544-6. |
|
| 765.
| | Dahl H, Fjaertoft G, Norsted T, et al. Reactivation of human herpesvirus 6 during pregnancy. J Infect Dis 1999;180:2035-8. |
|
| 766.
| | Horvat RT, Wood C, Josephs SF, et al. Transactivation of the human immunodeficiency virus promoter by human herpesvirus 6 (HHV- 6) strains GS and Z-29 in primary human T lymphocytes and identification of transactivating HHV-6(GS) gene fragments. J Virol 1991;65:2895-902. |
|
| 767.
| | Isegawa Y, Katahira J, Yamanishi K, et al. Reactivation of latent human immunodeficiency virus 1 by human herpesvirus 6 infection. Acta Virol 2007;51:13-20. |
|
| 768.
| | Fujiwara N, Namba H, Ohuchi R, et al. Monitoring of human herpesvirus-6 and -7 genomes in saliva samples of healthy adults by competitive quantitative PCR. J Med Virol 2000;61:208-13. |
|
| 769.
| | Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994;331:342-8. |
|
| 770.
| | Asano Y, Yoshikawa T, Suga S, et al. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics 1994;93:104-8. |
|
| 771.
| | Suga S, Yoshikawa T, Asano Y, et al. Clinical and virological analyses of 21 infants with exanthem subitum (roseola infantum) and central nervous system complications. Ann Neurol 1993;33:597-603. |
|
| 772.
| | Isaacson E, Glaser CA, Forghani B, et al. Evidence of human herpesvirus 6 infection in 4 immunocompetent patients with encephalitis. Clin Infect Dis 2005;40:890-3. |
|
| 773.
| | Mannonen L, Herrgrd E, Valmari P, et al. Primary human herpesvirus-6 infection in the central nervous system can cause severe disease. Pediatr Neurol 2007;37:186-91. |
|
| 774.
| | Caserta MT, Mock DJ, Dewhurst S. Human herpesvirus 6. Clin Infect Dis 2001;33:829-33. |
|
| 775.
| | Zerr DM, Frenkel LM, Huang ML, et al. Polymerase chain reaction diagnosis of primary human herpesvirus-6 infection in the acute care setting. J Pediatr 2006;149:480-5. |
|
| 776.
| | Leach CT. Human herpesvirus-6 and -7 infections in children: agents of roseola and other syndromes. Curr Opin Pediatr 2000;12:269-74. |
|
| 777.
| | Rappaport D, Engelhard D, Tagger G, et al. Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients. Transpl Infect Dis 2002;4:10-6. |
|
| 778.
| | Tokimassa S, Hara J, Osugi Y, et al. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant 2002;29:595-8. |
|
| 779.
| | Burns WH, Sanford GR. Susceptibility of human herpesvirus 6 to antivirals in vitro. J Infect Dis 1990;162:634-7. |
|
| 780.
| | De Clercq E, Naesens L, De Bolle L, et al. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001;11:381-95. |
|
| 781.
| | Rieux C, Gautheret-Dejean A, Challine-Lehmann D, et al. Human herpesvirus-6 meningoencephalitis in a recipient of an unrelated allogeneic bone marrow transplantation. Transplantation 1998;65:1408-11. |
|
| 782.
| | Wang FZ, Linde A, Hgglund H, et al. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance? Clin Infect Dis 1999;28:562-8. Vol. 58 / RR-11 Recommendations and Reports 121 |
|
| 783.
| | Singh N, Paterson DL. Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 2000;69:2474-9. |
|
| 784.
| | Drobyski WR, Knox KK, Majewski D, et al. Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient. N Engl J Med 1994;330:1356-60. |
|
| 785.
| | Phlmann C, Schetelig J, Reuner U, et al. Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient. Clin Infect Dis 2007;44:e118-20. |
|
| 786.
| | Janoly-Dumenil A, Galambrun C, Basset T, et al. Human herpes virus-6 encephalitis in a paediatric bone marrow recipient: successful treatment with pharmacokinetic monitoring and high doses of ganciclovir. Bone Marrow Transplant 2006;38:769-70. |
|
| 787.
| | De Bolle L, Manichanh C, Agut H, et al. Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antiviral Res 2004;64:17-25. |
|
| 788.
| | Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996;335:233-41. |
|
| 789.
| | Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996;348:858-61. |
|
| 790.
| | Engels EA, Atkinson JO, Graubard BI, et al. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 2007;196:199-207. |
|
| 791.
| | Whitby D, Smith NA, Matthews S, et al. Human herpesvirus 8: seroepidemiology among women and detection in the genital tract of seropositive women. J Infect Dis 1999;179:234-6. |
|
| 792.
| | Goedert JJ, Kedes DH, Ganem D. Antibodies to human herpesvirus 8 in women and infants born in Haiti and the USA. Lancet 1997;349:1368. |
|
| 793.
| | Huang LM, Huang SY, Chen MY, et al. Geographical differences in human herpesvirus 8 seroepidemiology: a survey of 1,201 individuals in Asia. J Med Virol 2000;60:290-3. |
|
| 794.
| | Serraino D, Locatelli M, Songini M, et al. Human herpes virus-8 infection among pregnant women and their children: results from the Sardinia-IDDM Study 2. Int J Cancer 2001;91:740-1. |
|
| 795.
| | Casper C, Krantz E, Selke S, et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis 2007;195:30-6. |
|
| 796.
| | Mbulaiteye SM, Pfeiffer RM, Whitby D, et al. Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis 2003;187: 1780-5. |
|
| 797.
| | He J, Bhat G, Kankasa C, et al. Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother-child pairs with KS. J Infect Dis 1998;178: 1787-90. |
|
| 798.
| | Gessain A, Mauclere P, van Beveren M, et al. Human herpesvirus 8 primary infection occurs during childhood in Cameroon, Central Africa. Int J Cancer 1999;81:189-92. |
|
| 799.
| | Sitas F, Newton R, Boshoff C. Increasing probability of mother-tochild transmission of HHV-8 with increasing maternal antibody titer for HHV-8. N Engl J Med 1999;340:1923. |
|
| 800.
| | Calabro ML, Gasperini P, Barbierato M, et al. A search for human herpesvirus 8 (HHV-8) in HIV-1 infected mothers and their infants does not suggest vertical transmission of HHV-8. Int J Cancer 2000; 85:296-7. |
|
| 801.
| | Plancoulaine S, Abel L, van Beveren M, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet 2000;356:1062-5. |
|
| 802.
| | Malope BI, Pfeiffer RM, Mbisa G, et al. Transmission of Kaposi sarcomaassociated herpesvirus between mothers and children in a South African population. J Acquir Immune Defic Syndr 2007;44:351-5. |
|
| 803.
| | Casper C, Meier AS, Wald A, et al. Human herpesvirus 8 infection among adolescents in the REACH cohort. Arch Pediatr Adolesc Med 2006;160:937-42. |
|
| 804.
| | Cannon MJ, Dollard SC, Smith DK, et al. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med 2001;344:637-43. |
|
| 805.
| | Hladik W, Dollard SC, Mermin J, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006;355:1331-8. |
|
| 806.
| | Lisco A, Barbierato M, Fiore JR, et al. Pregnancy and human herpesvirus 8 reactivation in human immunodeficiency virus type 1-infected women. J Clin Microbiol 2006;44:3863-71. |
|
| 807.
| | Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996;173:1477-80. |
|
| 808.
| | Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996;10:1101-5. |
|
| 809.
| | Cannon JS, Hamzeh F, Moore S, et al. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol 1999;73:4786-93. |
|
| 810.
| | Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997;41:2754-6. |
|
| 811.
| | Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997;99:2082-6. |
|
| 812.
| | Robles R, Lugo D, Gee L, et al. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:34-8. |
|
| 813.
| | Cannon MJ, Laney AS, Pellett PE. Human herpesvirus 8: current issues. Clin Infect Dis 2003;37:82-7. |
|
| 814.
| | Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999;282:2220-6. |
|
| 815.
| | Ziegler JL, Katongole-Mbidde E. Kaposi's sarcoma in childhood: an analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer 1996;65:200-3. |
|
| 816.
| | Andreoni M, Sarmati L, Nicastri E, et al. Primary human herpesvirus 8 infection in immunocompetent children. JAMA 2002;287:1295-300. |
|
| 817.
| | Luppi M, P. B, TF. S, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 2000;343:1378-85. |
|
| 818.
| | Luppi M, Barozzi P, Rasini V, et al. Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation 2002;74:131-2. |
|
| 819.
| | Bhaduri-McIntosh S. Human herpesvirus-8: clinical features of an emerging viral pathogen. Pediatr Infect Dis J 2005;24:81-2. |
|
| 820.
| | Laney AS, Cannon MJ, Jaffe HW, et al. Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. AIDS 2007;21:1541-5. |
|
| 821.
| | Anderson LA, Goedert JJ. Tumor markers and treatments for Kaposi sarcoma. AIDS 2007;21:1637-9. |
|
| 822.
| | . Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma. Curr Opin Oncol 2005;17:447-55. |
|
| 823.
| | Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004;103:1632-4. |
|
| 824.
| | Aboulafia DM. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clin Infect Dis 2002;34:1660-2. |
|
| 825.
| | Crum-Cianflone NF, Wallace MR, Looney D. Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. AIDS 2006;20:1567-9. |
|
| 826.
| | Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005;19:635-44. |
|
| 827.
| | Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J clin Oncol 2005;23:5224-8. |
|
| 828.
| | Whitley R, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998;26:541-53. |
|
| 829.
| | Xu F, Lee FK, Morrow RA, et al. Seroprevalence of herpes simplex virus type 1 in children in the United States. J Pediatr 2007;151:374-7. |
|
| 830.
| | Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296:964-73. |
|
| 831.
| | Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11. |
|
| 832.
| | Whitley R, Davis EA, Suppapanya N. Incidence of neonatal herpes simplex virus infections in a managed-care population. Sex Transm Dis 2007;34:704-8. |
|
| 833.
| | Prober CG, Corey L, Brown ZA, et al. The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis 1992;15:1031-8. |
|
| 834.
| | Brown ZA, Wald A, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289:203-9. |
|
| 835.
| | Xu F, Markowitz LE, Gottlieb SL, et al. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. Am J Obstet Gynecol 2007;196:43.e1-6. |
|
| 836.
| | Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995;123:845-7. |
|
| 837.
| | Catalano PM, Merritt AO, Mead PB. Incidence of genital herpes simplex virus at the time of delivery in women with known risk factors. Am J Obstet Gynecol 1991;164:1303-6. |
|
| 838.
| | Hitti J, Watts DH, Burchett SK, et al. Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Am J Obstet Gynecol 1997;177:450-4. |
|
| 839.
| | Drake AL, John-Stewart GC, Wald A, et al. Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 2007;109(2 Pt 1):403-9. |
|
| 840.
| | Salvini F, Carminati G, Pinzani R, et al. Chronic ulcerative herpes simplex virus infection in HIV-infected children. AIDS Patient Care STDS 1997;11:421-8. |
|
| 841.
| | Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001;108:223-9. |
|
| 842.
| | Kimberlin DW. Herpes simplex virus infections of the newborn. Semin Perinatol 2007;31:19-25. |
|
| 843.
| | Gutierrez K, Arvin AM. Long term antiviral suppression after treatment for neonatal herpes infection. Pediatr Infect Dis J 2003;22:371-2. |
|
| 844.
| | Kimberlin DW, Powell D, Gruber W, et al. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J 1996;15:247-54. |
|
| 845.
| | Corey L, Adams HG, Brown ZA, et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983;98:958-72. |
|
| 846.
| | Kimberlin DW, Lakeman FD, Arvin AM, et al. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1996;174:1162-7. |
|
| 847.
| | Kimura H, Aso K, Kuzushima K, et al. Relapse of herpes simplex encephalitis in children. Pediatrics 1992;89(5 Pt 1):891-4. |
|
| 848.
| | Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004;190:693-6. |
|
| 849.
| | Scott LL, Hollier LM, McIntire D, et al. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol 2002;10:71-7. |
|
| 850.
| | Sheffield JS, Hollier LM, Hill JB, et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol 2003;102:1396-403. |
|
| 851.
| | Sheffield JS, Hill JB, Hollier LM, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol 2006;108:141-7. |
|
| 852.
| | Kimberlin DW. Herpes simplex virus infections in neonates and early childhood. Semin Pediatr Infect Dis 2005;16:271-81. |
|
| 853.
| | Haddad J, Langer B, Astruc D, et al. Oral acyclovir and recurrent genital herpes during late pregnancy. Obstet Gynecol 1993;82:102-4. |
|
| 854.
| | American College of Obstetricians and Gynecologists. Management of herpes in pregnancy. ACLG Practice Bulletin 8. Washington DC: American College of Obstetricians and Gynecologists; 1999. |
|
| 855.
| | Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 2006;43:347-56. |
|
| 856.
| | Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001;108:230-8. |
|
| 857.
| | Balfour HH, Jr. Antiviral drugs. N Engl J Med 1999;340:1255-68. |
|
| 858.
| | Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998;177:48-56. |
|
| 859.
| | Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998;128:21-8. |
|
| 860.
| | Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, doubleblind, placebo-controlled trial. Clin Infect Dis 2006;42:8-13. Vol. 58 / RR-11 Recommendations and Reports 123 |
|
| 861.
| | Spruance S, Bodsworth N, Resnick H, et al. Single-dose, patientinitiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006;55:47-53. |
|
| 862.
| | Eksborg S, Pal N, Kalin M, et al. Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? Med Pediatr Oncol 2002;38;240-6. |
|
| 863.
| | Eksborg S. The pharmacokinetics of antiviral therapy in paediatric patients. Herpes 2003;10:66-71. |
|
| 864.
| | Balfour HH, Jr, Benson C, Braun J, et al. Management of acyclovirresistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994;7:254-60. |
|
| 865.
| | Lateef F, Don PC, Kaufmann M, et al. Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. Arch Dermatol 1998;134:1169-70. |
|
| 866.
| | Blot N, Schneider P, Young P, et al. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant 2000;26:903-5. |
|
| 867.
| | Munoz N, Castellsagué X, de González AB, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(S3):S1-S10. |
|
| 868.
| | Gutman LT, St Claire K, Herman-Giddens ME, et al. Evaluation of sexually abused and nonabused young girls for intravaginal human papillomavirus infection. Am J Dis Child 1992;146:694-9. |
|
| 869.
| | Beutner KR, Reitano MV, Richwald GA, et al. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin Infect Dis 1998;27:796-806. |
|
| 870.
| | Rintala M, Grénman SE, J?rvenkyl? ME, et al. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis 2005;41:1728-33. |
|
| 871.
| | Smith EM, Ritchie JM, Yankowitz J, et al. Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission. Sex Transm Dis 2004;31:57-62. |
|
| 872.
| | Hernandez-Giron C, Smith JS, Lorincz A, et al. High-risk human papillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico. Sex Transm Dis 2005;32:613-8. |
|
| 873.
| | Chan PK, Chang AR, Tam WH, et al. Prevalence and genotype distribution of cervical human papillomavirus infection: comparison between pregnant women and non-pregnant controls. J Med Virol 2002;67:583-8. |
|
| 874.
| | Fife KH, Katz BP, Brizendine EJ, et al. Cervical human papillomavirus deoxyribonucleic acid persists throughout pregnancy and decreases in the postpartum period. Am J Obstet Gynecol 1999;180:1110-4. |
|
| 875.
| | Hagensee ME, Cameron JE, Leigh JE, et al. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004;328:57-63. |
|
| 876.
| | Moscicki AB, Ellenberg JH, Vermund SH, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000;154:127-34. |
|
| 877.
| | Bollen LJ, Chuachoowong R, Kilmarx PH, et al. Human papillomavirus (HPV) detection among human immunodeficiency virus-infected pregnant Thai women: implications for future HPV immunization. Sex Transm Dis 2006;33:259-64. |
|
| 878.
| | Armbruster-Moraes E, Ioshimoto LM, Leo E, et al. Presence of human papillomavirus DNA in amniotic fluids of pregnant women with cervical lesions. Gynecol Oncol 1994;54:152-8. |
|
| 879.
| | Tseng CJ, Lin CY, Wang RL, et al. Possible transplacental transmission of human papillomaviruses. Am J Obstet Gynecol 1992;166(1 Pt 1): 35-40. |
|
| 880.
| | Tseng CJ, Liang CC, Soong YK, et al. Perinatal transmission of human papillomavirus in infants: relationship between infection rate and mode of delivery. Obstet Gynecol 1998;91:92-6. |
|
| 881.
| | Tenti P, Zappatore R, Migliora P, et al. Perinatal transmission of human papillomavirus from gravidas with latent infections. Obstet Gynecol 1999;93:475-9. |
|
| 882.
| | Smith EM, Swarnavel S, Ritchie JM, et al. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J 2007;26:836-40. |
|
| 883.
| | Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002. |
|
| 884.
| | Burchell AN, Winer RL, de Sanjosé S, et al. Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006;24:S52-61. |
|
| 885.
| | Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26. |
|
| 886.
| | Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006;354:2645-54. |
|
| 887.
| | Munoz N, Méndez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077-87. |
|
| 888.
| | Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;191:182-92. |
|
| 889.
| | Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277-84. |
|
| 890.
| | Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 2004;189:46-50. |
|
| 891.
| | Winer RL, Feng Q, Hughes JP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 2008;197:279-82. |
|
| 892.
| | Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8. |
|
| 893.
| | Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005;97:577-86. |
|
| 894.
| | Moscicki AB, Ellenberg JH, Farhat S, et al. Persistence of human papillomavirus infection in HIV-infected and HIV-uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004;190:37-45. |
|
| 895.
| | Moscicki AB, Schiffman M, Kjaer S, et al. Updating the natural history of HPV and anogenital cancer. Vaccine 2006;24(Suppl 3):S42-51. |
|
| 896.
| | Moscicki AB, Durako SJ, Houser J, et al. Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescents. AIDS 2003;17:311-20. 124 MMWR September 4, 2009 |
|
| 897.
| | Palefsky J. HPV infection and HPV-associated neoplasia in immunocompromised women. Int J Gynaecol Obstet 2006;94(Suppl 1): S56-64. |
|
| 898.
| | Palefsky J, Holly EA, Ralston ML, et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001;183:383-91. |
|
| 899.
| | Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-10. |
|
| 900.
| | Moscicki A, Burt VG, Kanowitz S, et al. The significance of squamous metaplasia in the development of low grade squamous intraepithelial lesions in young women. Cancer 1999;85:1139-44. |
|
| 901.
| | Moscicki AB, Ellenberg JH, Crowley-Nowick P, et al. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004;190:1413-21. |
|
| 902.
| | Arbyn M, Sasieni P, Meijer CJ, et al. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(Suppl 3): S78-89. |
|
| 903.
| | Wright TC, Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007;197:340-5. |
|
| 904.
| | The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27. |
|
| 905.
| | Garland S, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43. |
|
| 906.
| | Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70. |
|
| 907.
| | CDC. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-2). Available at http://www.cdc.gov/mmwr/ pdf/rr/rr5602.pdf. Accessed June 13, 2009. |
|
| 908.
| | Weinberg A, Song LY, Handelsman E, et al. Safety and immunogenicity of a quadrivalent vaccine to prevent human papilloma virus (HPV) infection in HIV-infected children: IMPAACT P1047. 15th Conference on Retroviruses and Opportunistic Infections, Feb 3-6, 2008, Boston MA, paper 619a. |
|
| 909.
| | Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999;281:1822-9. |
|
| 910.
| | Konstantinopoulos P, Schlecht HP, Bryan B, et al. HIV-associated anal squamous cell cancer: an otherwise preventable disease. J Clin Oncol 2006;24:4516-7. |
|
| 911.
| | De Panfilis G, Melzani G, Mori G, et al. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis 2002;29:121-5. |
|
| 912.
| | Silverberg MJ, Ahdieh L, Munoz A, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002;29:427-35. |
|
| 913.
| | Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation 2002;73:661-2. |
|
| 914.
| | King MD, Reznik DA, O' Daniels CM, et al. Human papillomavirusassociated oral warts among human immunodeficiency virusseropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002;34:641-8. |
|
| 915.
| | Hodgson TA, Greenspan D, Greenspan JS. Oral lesions of HIV disease and HAART in industrialized countries. Adv Dent Res 2006;19:57-62. |
|
| 916.
| | Baccaglini L, Atkinson JC, Patton LL, et al. Management of oral lesions in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:e1-23. |
|
| 917.
| | Reeves W, Ruparelia SS, Swanson KI, et al. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2003;129:976-82. |
|
| 918.
| | Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004;364: 1678-83. |
|
| 919.
| | Wright TC, Koulos J, Schnoll F, et al. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. Gynecol Oncol 1994;55:253-8. |
|
| 920.
| | Fruchter RG, Maiman M, Sedlis A, et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996;87:338-44. |
|
| 921.
| | Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness of screening for anal squamous intraepithelial lesionsi homosexual and bisexual HIV-positive men. JAMA 1999;281:1822-9. |
|
| 922.
| | Kurman RJ, Henson DE, Herbst AL, et al. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994;271:1866-9. |
|
| 923.
| | Maiman M, Watts DH, Andersen J, et al. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial. Obstet Gynecol 1999;94:954-61. |
|
| 924.
| | Astrom KE, Mancall EL, Richardson EP J. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958;81:93-111. |
|
| 925.
| | Stolt A., Sasnauskas K, Koskela P, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003;84(Pt 6):1499-504. |
|
| 926.
| | Rodrigues C, Pinto D, Medeiros R. Molecular epidemiology characterization of the urinary excretion of polyomavirus in healthy individuals from Portugal-a Southern European population. J Med Virol 2007;79:1194-8. |
|
| 927.
| | Gu ZY, Li Q, Si YL, et al. Prevalence of BK virus and JC virus in peripheral blood leukocytes and normal arterial walls in healthy individuals in China. J Med Virol 2003;70:600-5. |
|
| 928.
| | Ciuta ST, Boros S, Napoli PA, et al. Predictors of survival in children with acquired immunodeficiency syndrome in Italy, 1983 to 1995. AIDS Patient Care STDS 1998;12:629-37. |
|
| 929.
| | Araujo AP, Pereira HS, Oliveira RH, et al. Progressive multifocal leukoencephalopathy in a child with acquired immunodeficiency syndrome (AIDS). Arg Neuropsiguiatr 1997;55:122-5. |
|
| 930.
| | Robinson LG, Chiriboga CA, Champion SE, et al. Progressive multifocal leukoencephalopathy successfully treated with highly active antiretroviral therapy and cidofovir in an adolescent infected with perinatal human immunodeficiency virus (HIV). J Child Neurol 2004;19:35-8. |
|
| 931.
| | Wilmshurst JM, Burgess J, Hartley P, et al. Specific neurologic complications of human immunodeficiency virus type 1 (HIV-1) infection in children. J Child Neurol 2006;21:788-94. |
|
| 932.
| | Shah I, Chudgar P. Progressive multifocal leukoencephalopathy (PML) presenting as intractable dystonia in an HIV-infected child. J Trop Pediatr 2005;51:380-2. |
|
| 933.
| | Berger JR, Scott G, Albrecht J, et al. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS 1992;6: 837-41. |
|
| 934.
| | Liptai Z, Papp E, Barsi P, et al. Progressive multifocal leukoencephalopathy in an HIV-infected child. Neuropediatrics 2007;38:32-5. |
|
| 935.
| | Angelini L, Pietrogrande MC, Delle Piane MR, et al. Progressive multifocal leukoencephalopathy in a child with hyperimmunoglobulin E recurrent infection syndrome and review of the literature. Neuropediatrics 2001;32:250-5. |
|
| 936.
| | Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003;9(Suppl 1): 47-53. |
|
| 937.
| | Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004;17:365-70. |
|
| 938.
| | Berenguer JP, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003;36:1047-52. |
|
| 939.
| | Mamidi A, DeSimone JA, Pomerantz RJ. Central nervous system infections in individuals with HIV-1 infection. J Neurovirol 2002;8: 158-67. |
|
| 940.
| | Bossolasco S, Calori G, Moretti F, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 2005;40:738-44. |
|
| 941.
| | Drake AK, Loy CT, Brew BJ, et al. Human immunodeficiency virusassociated progressive multifocal leucoencephalopathy: epidemiology and predictive factors for prolonged survival. Eur J Neurol 2007;14: 418-23. |
|
| 942.
| | Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998;338:1345-51. |
|
| 943.
| | Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002; 16:1791-7. |
|
| 944.
| | Geschwind MD, Skolasky RI, Royal WS, et al. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 2001;7:353-7. |
|
| 945.
| | Giudici B, Vaz B, Bossolasco S, et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 2000;30:95-9. |
|
| 946.
| | Safdar A, Rubocki RJ, Horvath JA, et al. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002;35:1250-7. |
|
| 947.
| | Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003;9(Suppl 1):88-92. |
|
| 948.
| | D'Amico R, Sarkar S, Yusuff J, et al. Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy. Scand J Infect Dis 2007;39:347-50. |
|
| 949.
| | Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003;9(Suppl 1):25-31. |
|
| 950.
| | Gershon A, Seward J, Takahashi M. Varicella vaccine. In: Plotkin S, Orenstein W, Offit PA. Vaccine. 5th ed. Philadelphia, PA: Saunders;2008:915-958. |
|
| 951.
| | Gershon A, Mervish N, LaRussa P, et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis 1997;176:1496-500. |
|
| 952.
| | Derryck A, LaRussa P, Steinberg S, et al. Varicella and zoster in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1998;17:931-3. |
|
| 953.
| | Hambelton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev 2005;18:70-80. |
|
| 954.
| | LaRussa P, Steinberg SP, Seeman MD, et al. Determination of immunity to varicella-zoster virus by means of an intradermal skin test. J Infect Dis 1985;152:869-75. |
|
| 955.
| | Veenstra J, Krol A, van Praag RM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995; 9:1153-8. |
|
| 956.
| | Chen JJ, Zhu Z, Gershon AA, et al. Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell 2004;119:915-26. |
|
| 957.
| | Ross AH. Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med 1962;267:369-76. |
|
| 958.
| | Clark R, Wilson S, Williams T. Varicella immunity in women infected with the human immunodeficiency virus. Clin Infect Dis 1994;19:1165-6. |
|
| 959.
| | Schulze A, Dietzsch HJ. The natural history of varicella embryopathy: a 25-year follow-up. J Pediatr 2000;137:871-4. |
|
| 960.
| | Arvin AM. Varicella-zoster virus. Clin Microbiol Reb 1996:9:361-81. |
|
| 961.
| | Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994;330:901-5. |
|
| 962.
| | Ussery XT, Annunziato P, Gershon AA, et al. Congenital varicellazoster virus infection and Barrett's esophagus. J Infect Dis 1998; 178:539-43. |
|
| 963.
| | von Seidlein L, Gillette SG, Bryson Y, et al. Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunodeficiency virus type 1. J Pediatr 1996;128:52-7. |
|
| 964.
| | Martinez E, Gatell J, Morán Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998;27:1510-3. |
|
| 965.
| | Jura E, Chadwick EG, Josephs SH, et al. Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1989;8:586-90. |
|
| 966.
| | Kelley R, Mancao M, Lee F, et al. Varicella in children with perinatally acquired human immunodeficiency virus infection. J Pediatr 1994;124:271-3. |
|
| 967.
| | Leibovitz E, Cooper D, Giurgiutiu D, et al. Varicella-zoster virus infection in Romanian children infected with the human immunodeficiency virus. Pediatrics 1993;92:838-42. |
|
| 968.
| | Leibovitz E, Kaul A, Rigaud M, et al. Chronic varicella zoster in a child infected with human immunodeficiency virus: case report and review of the literature. Cutis 1992;49:27-31. 126 MMWR September 4, 2009 |
|
| 969.
| | Pahwa S, Biron K, Lim W, et al. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 1988;260:2879-82. |
|
| 970.
| | Silliman CC, Tedder D, Ogle JW, et al. Unsuspected varicella-zoster virus encephalitis in a child with acquired immunodeficiency syndrome. J Pediatr 1993;123:418-22. |
|
| 971.
| | Gershon A, Chen J, LaRussa P, et al. Varicella-zoster virus. In: Murray PR, Baron EJ, Jorgenson JH, Pfaller MA, Yolken RH, eds. Manual of clinical microbiology. 8th ed. Washington, DC: ASM Press: 2007;1319-30. |
|
| 972.
| | Purdy KW, Heckenlively JR, Church JA, et al. Progressive outer retinal necrosis caused by varicella-zoster virus in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2003;22:384-6. |
|
| 973.
| | Hellinger WC, Bolling JP, Smith TF, et al. Varicella-zoster virus retinitis in a patient with AIDS-related complex: case report and brief review of the acute retinal necrosis syndrome. Clin Infect Dis 1993;16:208-12. |
|
| 974.
| | Engstrom RE, Jr, Holland GN, Margolis TP, et al. The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology 1994;101:1488-502. |
|
| 975.
| | Franco-Paredes C, Bellehemeur T, Merchant A, et al. Aseptic meningitis and optic neuritis preceding varicella-zoster progressive outer retinal necrosis in a patient with AIDS. AIDS 2002;16:1045-9. |
|
| 976.
| | Levin MJ, Dahl KM, Weinberg A, et al. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 2003;188:954-9. |
|
| 977.
| | Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIVinfected children with varicella vaccine. J Pediatr 2001;139:305-10. |
|
| 978.
| | Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006;194:247-55. |
|
| 979.
| | Bekker V, Westerlaken GH, Scherpbier H, et al. Varicella vaccination in HIV-1-infected children after immune reconstitution. AIDS 2006;20:2321-9. |
|
| 980.
| | Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000;19:916-23. |
|
| 981.
| | Kramer JM, LaRussa P, Tsai WC, et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 2001;108:E39. |
|
| 982.
| | CDC. A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR 2006;55:209-10. |
|
| 983.
| | Asano Y, Yoshikawa T, Suga S, et al. Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 1993;92:219-22. |
|
| 984.
| | Huang YC, Lin TY, CH C. Acyclovir prophylaxis of varicella after household exposure. Pediatr Infect Dis J 1995;14:152-4. |
|
| 985.
| | Lin TY, Huang YC, Ning HC, et al. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997;16:1162-5. |
|
| 986.
| | Balfour HH, Jr, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983;308:1448-53. |
|
| 987.
| | Yin PD, Kurup SK, Fischer SH, et al. Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: successful management with intravitreal injections and monitoring with quantitative PCR. J Clin Virol 2007;38:254-9. |
|
| 988.
| | Austin RB. Progressive outer retinal necrosis syndrome: a comprehensive review of its clinical presentation, relationship to immune system status, and management. Clin Eye Vis Care 2000;12:119-29. |
|
| 989.
| | Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44(Suppl 1): S1-26. |
|
| 990.
| | Dekker CL, Prober CG. Pediatric uses of valacyclovir, penciclovir and famciclovir. Pediatr Infect Dis J 2001;20:1079-81. |
|
| 991.
| | Domingo P, Torres OH, Ris J, et al. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med 2001;110:605-9. |
|
| 992.
| | Heininger U, Seward JF. Varicella. Lancet 2006;368:1365-76. |
|
| 993.
| | Enright A, Prober C. Antiviral therapy in children with varicella zoster virus and herpes simplex virus infections. Herpes 2003;10:32-7. |
|
HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2013, Regents of the University of California.